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Targeting the Aurora A/N-Myc Protein-Protein Interaction in 
Neuroblastoma 
Abstract 
Neuroblastoma is a rare cancer affecting children, with around one hundred new 
cases each year in the UK. Mortality rates are around 40% but current intensive 
treatment regimens result in long-term health effects in the majority of survivors.1 
For these reasons, novel approaches to neuroblastoma treatment are required to 
improve survival rates and prevent chronic health problems following treatment.  
The protein-protein interaction between Aurora kinase A and the transcription 
factor N-myc has been shown to be important in neuroblastoma. There is evidence 
that neuroblastoma cells become “addicted” to N-myc stabilisation by interaction 
with Aurora A and the disruption of this interaction leads to N-myc degradation and 
neuroblastoma cell death.2 
The identification of compounds which disrupt the Aurora A/N-myc complex, either 
directly or by acting at an allosteric site, could have therapeutic potential and may 
avoid the significant toxicity of current treatments. In this work, various methods, 
including virtual high-throughput screening, high-throughput crystallography, in 
vitro screening and traditional medicinal chemistry approaches, were combined to 
assess the feasibility of several approaches to the modulation of Aurora A activity 
and the potential to disrupt the Aurora A/N-myc protein-protein interaction.  
Computational analysis of possible binding sites of Aurora A provided some 
guidance in directing the project to the most promising strategies to develop a 
small molecule inhibitor of the key protein-protein interaction. In silico screening 
proved a useful tool to guide the selection of compounds taken forwards for crystal 
soaking and in vitro assays, which allowed the identification of a small number of 
fragments as potential starting points for the development of the first type III Aurora 
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Chapter 1 Introduction 
 Neuroblastoma 
Neuroblastoma is a rare cancer first defined in 19103 which affects the sympathetic 
nervous system, is diagnosed in childhood (adults are affected exceedingly rarely) 
and is identified in approximately 100 children each year in the UK.1 It is the fourth 
most common cancer type in children under 15 years of age, behind leukaemias, 
lymphomas and intracranial solid tumours,4,5 a ranking which has remained 
consistent since the 1970s,6 but is the most common cancer for new-borns in the 
UK.4 However, neuroblastoma is responsible for a disproportionate number of 
childhood deaths (under 15 years) from cancer,1 with a mortality rate second only 
to malignant bone tumours4 despite some improvement in survival in recent 
decades.6  
The average age at diagnosis for these patients is 17 months and symptoms can 
vary greatly depending on the site of the primary tumour and subsequent organ 
involvement.1 Family history of neuroblastoma is seen in a very small number of 
cases (1-2%) and these patients are often diagnosed earlier, at an average age of 
9 months.1,7  
Neuroblastoma has a highly variable prognosis depending on disease stage at 
diagnosis, affected sites, age and any underlying conditions.7 Overall, 
neuroblastoma has a mortality rate close to 40%,4 but a subset of neuroblastoma 
patients, known as “high-risk”, have a higher mortality rate (close to 60%) and are 
identified by widespread metastasis, amplification of the MYCN gene and age at 
diagnosis over 18 months.8 
1.1.1 Diagnosis 
Diagnosis of neuroblastoma is usually made form stage 2 onwards, when 





specific pain or malaise are reported. Symptoms can include constipation, 
diarrhoea, swelling or twitching,1 depending on the affected organs (Table 1.1). 
Table 1.1 Possible symptoms of neuroblastoma depending on site or type of 
tumour1 
Affected Area or Tumour Type Possible Symptoms 
Abdomen Swelling 
Constipation or urinary retention (due 
to compression) 
Orbital region Proptosis and “raccoon eyes” 
(periorbital ecchymosis) 
Liver Jaundice 
Vasoactive intestinal peptide 
secreting tumours 
Diarrhoea 
Catecholamine-secreting tumours Flushing and sweating 
Cerebellum “Opsoclonus-myoclonus” syndrome 
(eye twitches, gait problems, mutism, 
vomiting) 
Extensive metastasis Generally unwell, probably 
combinations of the above symptoms 
 
Neuroblastoma may also be detected during routine testing of apparently healthy 
children if increased levels of catecholamine derivatives in urine are observed, 
although these increased levels can be caused by other factors (including 
consumption of olives) and can produce false positives.9 Some biomarkers can 
also be measured in serum, which are not specific to neuroblastoma and are 





Treatment decisions in neuroblastoma depend on the stage of disease. Thus, 
accurate staging techniques play a vital role in determining the outcome and long-
term effects for patients. An initial ultrasound scan and subsequent CT scans give 
an indication of the extent of metastasis and an initial assessment of tumour 
resectability. Where bone metastasis is suspected, Meta-iodobenzylguanidine 
(MIBG) bone scintigraphy is performed for an accurate indication of disease 
stage.1,10  
1.1.2 Treatment 
Stage 4S disease, an unusual neuroblastoma sub-type, often only requires 
observation. Exceptions occur when patients experience symptoms associated 
with tumour positioning in the affected organs (for example jaundice) or in rare 
cases where stage 4S disease progresses to a more malignant phenotype.1 
In general, “higher-risk” patients undergo more intensive treatment regimens. In 
low-risk cases surgery is often all that is required and radiotherapy is actively 
discouraged as the risk of long-term effects outweigh any benefit gained.1 
By definition intermediate-risk patients have tumours which are not completely 
resectable. In these cases chemotherapy including etoposide and platinum-based 
compounds are used, after which surgery may be possible. If there is progression 
despite the use of these treatments, radiotherapy may be considered provided 
there is no spinal involvement.1 
For high-risk patients intensive, multimodal therapy is employed. In these cases 
chemotherapy involves etoposide and carboplatin, as well as doxorubicin, 
cyclophosphamide and vincristine accompanied by radiotherapy, myeloblative 
therapy and haematopoietic stem cell transplants (Figure 1.1).7  
The most recent new treatment for neuroblastoma was approved in the EU in 2017 
for high-risk neuroblastoma patients over 12 months old.11 Dinutuximab is an anti-
GD2 antibody and targets the GD2 ganglioside which is overexpressed in 





Following treatment, a common problem in high-risk patients is Minimal Residual 
Disease (MRD), which triggers relapse in around 50% of cases, usually from 
remaining neuroblastoma cells in the bone marrow.1 This form of relapse has a 
very poor prognosis as the tumours are often resistant to chemotherapy and 
patients have not recovered from the initial treatment, leaving very few options. 
New treatments targeting MRD involve immunotherapy to target diganglioside on 
any remaining neuroblastoma cells.1,13 
Chronic health problems are a significant concern for survivors of childhood 
cancers, with more intensive treatments more likely to cause long-term effects 
such as infertility,14 pulmonary effects15 and mental health concerns including post-
traumatic stress and suicide ideation.16 The majority of late deaths of 
neuroblastoma survivors are due to neuroblastoma relapse and 15% are due to the 
occurrence of a second malignant cancer, most commonly breast, thyroid and 







Figure 1.1 Treatment options and outcomes based on neuroblastoma risk 







 Aurora A and Interacting Proteins 
A number of proteins have been identified with the potential for involvement with 
neuroblastoma. Aurora A and N-myc have both been suggested as possible 
targets in the development of novel treatments for neuroblastoma.2 The Aurora 
A/N-myc protein-protein interaction is made up of two proteins which both perform 
vital roles, both in healthy cells and in cancer.2,17 
1.2.1 Aurora A 
Aurora A is a serine/threonine protein kinase made up of a -sheet domain at the 
N-terminus and 6 -helices, with the two domains connected by a “hinge” region.  
Aurora A interacts with an array of proteins and substrates, in both health and 
disease.17–19 Until recently, the Aurora kinases were not grouped with any of the 
kinase families and were instead grouped with “other” kinases. Using Hidden 
Markov Models (HMM), the Aurora kinases were able to be grouped with CAMK 
kinases.20 
All human kinases have multiple common features. All kinases contain an ATP-
binding site, which is highly conserved across all members of the kinase family. 
The tertiary structures of kinases are also similar, with N-terminal and C-terminal 
lobes formed of a -sheet region and multiple -helices, respectively.21  
For an active kinase, further features must be present. The flexible activation loop 
contains a DFG motif, which must be in a DFG-in conformation in the active 
kinase, with the key Asp side chain directed towards the active site.21 This feature 
alone is not sufficient for kinase activity, so a kinase could be inactive whilst still in 
the DFG-in conformation. A further key feature of an active kinase is the formation 
of a salt bridge between a Lys residue from the -sheet region and a Glu side 
chain on the C-helix.21 
Finally, the correct alignment of two hydrophobic spines is required for activity. The 
regulatory R-spine is responsible for ensuring the correct positioning of substrates 





helix and -sheet regions. In an active kinase the R-spine should be mostly linear. 
The catalytic C-spine is involved in alignment of ATP in preparation for catalysis 
and again involves residues from both the C- and N-lobes of the kinases and the 
adenine portion of ATP.22 
 
1.2.1.1 Aurora A in Healthy Cells 
Aurora A was first discovered in 1990 as one of a family of three proteins (Aurora 
A, B and C).23 All three Aurora proteins function as kinases, interacting with a 
variety of other proteins and phosphorylating a range of substrates. When active, 
Aurora A is autophosphorylated at Thr288.24  
Aurora kinase A is inactive for most of the cell cycle and is found in centrosomes.18 
During the late G2 phase Aurora A interacts with and is activated by the protein 
Ajuba. Ajuba is both a substrate and activator for Aurora A: only phosphorylated 
Ajuba can form a complex with Aurora A.25 Active Aurora A then forms a complex 
with TPX2, which is also both a substrate and activator of Aurora A and this 
interaction can trigger mitosis (Figure 1.3).17,18, 24,26  
During the early stages of mitosis Aurora A moves to the mitotic spindles and the 
Aurora A/TPX2 complex helps to ensure correct bipolar spindle assembly and loss 
of either of these proteins results in loose or unstable spindles.17,24,25  
During metaphase Aurora A phosphorylates the protein CENP-A at Ser7 (Figure 
1.3). It is believed that phosphorylated CENP-A plays a crucial role in attaching 
microtubules to the kinetochore, which provides a framework to align 
chromosomes before separation. Therefore, the phosphorylation of CENP-A by 
Aurora A indirectly affects chromosome alignment and separation.17  
Levels of Aurora A are reduced from the metaphase-anaphase transition onwards. 
The anaphase-promoting complex (APC) targets Aurora A for proteasomal 
degradation using adapter proteins which target the “D-box” (destruction box) of 
Aurora A, a short sequence (RxxL) highly conserved across all three members of 





Table 1.2).17,27 The D-box sequence is crucial for reducing levels of active Aurora A 
to complete mitosis. 
 
Figure 1.2 Stages of mitosis 
 
Table 1.2 D-box sequences for Aurora A, B and C in different species 
Protein Species Residue 
numbers 
Sequence 
Aurora A Homo sapiens 371-374 …HNPSQRPMLREVLEHPW… 
Xenopus laevis 378-381 …HNPNHRLPLKGVLEHPW… 
Mus musculus 384-387 …HNASQRLTLAEVLEHPW… 
Aurora B Homo sapiens 315-318 …HNPSERLPLAQVSAHPW… 
Xenopus laevis 331-334 …YHPPQRLPLKGVMEHPW… 
Mus musculus 320-323 …HNPWQRLPLAEVAAHPW… 
Aurora C Homo sapiens 281-284 …YQPLERLPLAQILKHPW… 







Figure 1.3 Key events and interactions of Aurora A during the cell cycle; proteins 
which either form interactions with, or are substrates of, Aurora A are red.17,18 
 
1.2.1.2 Aurora A Kinase Activity in Cancer 
Aurora A has been implicated in cancer on its own, regardless of interaction with 
N-myc.28,29 As mentioned above, levels of activated Aurora A increase from the 
late G2 phase into mitosis.17 However, some cancers show increased Aurora A at 
all stages of the cell cycle and Aurora A is not usually restricted to the nucleus in 
cancer.17 For this reason, phosphorylation of various proteins is seen in cancer as 






Furthermore, there is a cell cycle checkpoint between the G2 and M phases, which 
can prevent cells with damaged DNA from entering mitosis.17 When Aurora A 
protein levels are unusually high, DNA-damage signals, which would normally 
inhibit Aurora A, still leave high levels of active Aurora A which can override the 
checkpoint and allows the cell to enter mitosis.17 
Finally, Aurora A appears to have a complicated relationship with the tumour 
suppressor p53.31 It has been reported that p53 can abrogate the oncogenic 
activity of Aurora A. However, there is also evidence that p53 is a substrate of 
Aurora A and phosphorylation at Ser215 inhibits the transcriptional role of p53. In 
addition, phosphorylation of p53 at Ser315 prepares p53 for export from the 
nucleus, where it is a substrate for MDM2-mediated degradation (Figure 1.4).17  
 
Figure 1.4 A summary of the relationship between p53 and Aurora A: p53 can 
block the oncogenic activity of Aurora A but phosphorylation of p53 at Ser215 
or Ser315 by Aurora A results in loss of transcriptional activity or nuclear 
export and degradation, respectively17 
 
Inhibition of the kinase activity of Aurora A could be a useful target for new cancer 
treatments, preventing the involvement of Aurora A in the cancerous pathways 
described. Aurora A kinase activity is essential for mitosis so cell death arising from 
kinase inhibition might be expected. 
1.2.1.3 Aurora A Interactions in Cancer 
As mentioned above, the interaction between Aurora A and TPX2 is important in 
initiating mitosis (Figure 1.3). When TPX2 binds, the activation loop of Aurora A 
stretches slightly so substrates are better able to bind in the active site. The 





at Thr288 by protein phosphatase 1 (PP1).32 TPX2 binding also stimulates Aurora 
A autophosphorylation at Thr288 and subsequent Aurora A activation.33,34 In the 
event of DNA damage (especially double strand breakage) mitosis is inhibited by 
decreasing TPX2 levels and activating the anaphase promoting complex which 
promotes Aurora A degradation and G2 arrest.32 
In some hepatocellular carcinoma (HCC) cell lines an interaction between Aurora A 
and the transcription factor c-myc has been seen, especially in cases with p53 
mutations. Aurora A helps to stabilise c-myc, allowing c-myc to support tumour cell 
proliferation and survival. Liver cirrhosis is the biggest risk factor for HCC. Although 
the underlying mechanisms are not fully understood, a possible explanation 
proposed by Dauch et al. suggests the requirement for liver regeneration results in 
increased c-myc, eventually leading to evasion of the G2/M cell cycle arrest.35  
1.2.2 N-myc 
N-myc is one member of a family of three proteins (N-myc, c-myc and L-myc), 
which all function as transcription factors and together the myc family are thought 
to regulate the transcription of one third of the genome.31 They are particularly 
involved in promoting the transcription of proteins involved in cell growth and 
proliferation, as well as angiogenesis and inhibition of differentiation, all key events 
in cancer.36 
N-myc is absolutely essential for proper development: knockout of the MYCN gene 
is embryonic lethal in mice due to widespread organ failure resulting from 
insufficient proliferation. However, myc proteins are only detected at low levels in 
non-dividing cells, if at all, so although myc proteins are important, they are not 
required in all cell types at all times.36 
As a transcription factor, N-myc binds to another protein, MAX (myc-associated 
factor X, Figure 1.5), via helix-loop-helix-leucine zipper regions on each of the 
proteins. Together, the N-myc/MAX complex binds to a variety of DNA sites, 





other proteins with similar helix-loop-helix-leucine zipper regions, which are 
believed to act as inhibitors of N-myc/MAX-mediated transcription.36,37 
 
 
Figure 1.5 Schematic of the interaction between N-myc and MAX: interaction 
between the two proteins is via helix-loop-helix regions (HLH, purple box); 









Figure 1.6 Diagram of the interactions of Aurora A with other key proteins, in 
reality the different binding sites are less distinct and may overlap 
 
1.2.3 TACC3 
TACC3 is a substrate and activator of Aurora A and this interaction is important for 
successful mitosis by ensuring correct central spindle formation.38 Overexpression 
of TACC3 has been implicated in various cancers and there has been some work 
towards identifying modulators of TACC3.39 A crystal structure of the Aurora 
A/TACC3 complex has been published, with the inactive form of Aurora A (Figure 
1.7).40 TACC3 is phosphorylated at Ser558 by Aurora A and the phosphorylated 
form of TACC3 is able to form an interaction with ch-TOG (colonic and hepatic 
tumor overexpressed gene), which in turn can form a TACC3-chTOG-clathrin 
complex which is believed to stabilise microtubules by crosslinking different 






Figure 1.7 The Aurora A/TACC3 interaction (PDB 5ODT)40 with Aurora A carbons 
shown in grey and TACC3 carbon in pink; ADP is shown (green sticks) in its 
binding site 
 Aurora A/N-myc in Neuroblastoma 
It has been demonstrated that increased levels of the Aurora A/N-myc complex 
correlates with a poorer prognosis in neuroblastoma. The complex protects N-myc 
from degradation, allowing it to continue to function as a transcription factor.43 
There is also evidence that neuroblastoma cells can become “addicted” to high 
levels of N-myc and reduction in the amount of N-myc in the cell can lead to 
apoptosis. Recently, the Aurora A/N-myc interaction has also been implicated in 





When in a complex with N-myc, both the ATP-binding site and the kinase active 
site of Aurora A are unaffected. The protein-protein interaction is shown in Figure 
1.8.  
 
Figure 1.8 The Aurora A/N-myc interaction with Aurora A carbons shown in grey 
and N-myc carbon and backbone in orange (PDB 5G1X).45 ADP is also 
shown (green sticks) in the ATP binding site. 
 
N-myc is protected from degradation by its interaction with Aurora A, which 
conceals and prevents access to two key sites of phosphorylation on N-myc.43 
When the Aurora A/N-myc complex separates, N-myc is first phosphorylated at 





phosphorylated, N-myc is ubiquitinated and targeted for proteasomal degradation 
by Fbxw7, a ubiquitin ligase (Figure 1.9).19, 37,45 
In vitro, shRNA (short hairpin RNA) has been used to knockdown MYCN, the gene 
encoding N-myc, in neuroblastoma cell lines.37 IMR32 and SH-EP cells were used 
which express amplified and single copy MYCN respectively. IMR32 cells appear 
to depend on high levels of N-myc, as MYCN knockdown gives a reduction in the 




Figure 1.9 Dissociation of the N-myc/Aurora A complex allows phosphorylation of 
N-myc at Thr58 and Ser62 by GSK3 and cyclin B/CDK1 respectively; 
phosphorylated N-myc is ubiquitinated by Fbxw7 and targeted for 
proteasomal degradation2,37 
 
A similar effect is seen when siRNAs (small interfering RNA) targeting AURKA 
(encoding Aurora A) are transfected into the same cell lines. IMR32 cells show 
lower proliferation rates whereas SH-EP cells are unaffected. In these studies 
AURKA knockdown did not induce apoptosis in IMR32 cells but did make them 







 Aurora A/N-myc 
The Bayliss lab has produced a crystal structure of the Aurora A/N-myc interaction 
at 1.72 Å resolution (Figure 1.8).45 Only one of the two -helices of N-myc are 
present, but the crystal structure is able to provide an insight into the relative 
positions of important binding sites of Aurora A and highlights some hydrogen 
bonding interactions between N-myc and Aurora A.  When Aurora A forms an 
interaction with N-myc, the active conformation of the kinase is observed.47 
A crystal structure has been published of Aurora A in complex with vNAR-D01,48 a 
single variable domain of the antigen receptor from sharks, which stabilised a 
conformation of Aurora A in which the salt bridge between Lys162 and Glu181 was 
broken, resulting in an inactive kinase state. This break in the salt bridge can also 
be seen in the crystal structures of Aurora A with some active site kinase 
inhibitors,49–54 so the identification of a drug-like compound which stabilises this 
inactive conformation of Aurora A may be useful.  As mentioned, the Aurora A/N-
myc interaction sees Aurora A in the active conformation, so confining Aurora A to 
the inactive conformation, with a misaligned R spine and C-helix, could generate 
an Aurora A conformation which is incompatible with N-myc binding, thus leading 
to N-myc degradation and neuroblastoma cell death.47 
 Kinase Inhibitors 
With over 500 kinases in the human kinome,55 many of which have been linked to 
disease, it is unsurprising that this class of proteins has become a major target 
class for new drugs. The high level of interest in small molecule modulators of 
kinases has necessitated the classification of kinase inhibitors into six distinct 
“types,” characterised by their mode of binding to the target protein (Table 1.3).21,56  
There are many examples of successful type I, I½ and II inhibitors, including 
crizotinib (1), a type I inhibitor of ALK and type I½B inhibitor of c-Met, gefitinib (2), a 
type I inhibitor of EGFR, and pazopanib (3, Figure 1.10), a type I inhibitor of 





conserved so achieving selectivity for a single kinase can be a challenge with ATP-
competitive inhibitors. Type A inhibitors, which extend beyond the main cleft of the 
ATP-binding site and are a subtype of type I, I½ and II inhibitors, may provide an 
opportunity to introduce selectivity.57 Conversely, the type B subgroup inhibitors 
occupy only the main cleft of the ATP-binding site.21 
There is currently only one type III kinase inhibitor, approved for use in advanced 
melanoma and non-small cell lung cancer with mutations in the BRAF gene.58 
Trametinib (4) is an inhibitor of MEK and computational models have suggested 
trametinib binds close to the ATP-binding site without competing with ATP, 







Figure 1.10 Type I-IV kinase inhibitor structures mentioned in this section, grouped 
by inhibition type 
 
Type IV inhibitors include sirolimus (5), temsirolimus (6) and everolimus (7), all of 
which act on the same target in the mTOR pathway.21 There are currently no 
clinical examples of type V inhibitors. Ibrutinib (8) and afatinib (9, Figure 1.11) are 
both examples of covalent type VI inhibitors. Both compounds react via Michael 






Figure 1.11 Type IV and VI kinase inhibitor structures mentioned in this section, 





Table 1.3 A summary of kinase inhibitor types 




Type I - ATP pocket Active ATP-
competitive 
Type I½ A ATP pocket 
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 Existing Aurora Inhibitors 
A number of Type I ATP-competitive inhibitors of Aurora A have been reported60–67: 
the MLN series of compounds are selective Aurora A kinase inhibitors and CD532 
is an Aurora A kinase inhibitor and an allosteric Aurora A/N-myc interaction 
inhibitor.31 The third compound which will be discussed, VX-680, is a non-selective 
Aurora kinase inhibitor. 
1.6.1 MLN Compounds 
MLN8054 (10) and its successor, MLN8237 (11) (Figure 1.12) inhibit the kinase 
activity of Aurora A and the crystal structure of Aurora A with MLN8054 shows this 
compound bound in the ATP binding site (PDB 2X81).49 
MLN8237 (11) is a specific Aurora kinase A inhibitor which has advanced to clinical 
trials for treatment of neuroblastoma under the name Alisertib.68 MLN8237 is an 
ATP-competitive inhibitor of Aurora A and is selective for Aurora A over Aurora B 
with IC50 values of 1.2 nM and 396.5 nM respectively.31 Evidence for selectivity 
within the aurora family is obtained by measurement of the levels of 
phosphorylated histone H3, which can be phosphorylated at Ser10 by both Aurora 
A and Aurora B.31 With a nonselective inhibitor, phosphorylated H3 levels decrease 
in a dose-dependent manner, as expected. However, with an Aurora A selective 
inhibitor, there is an initial increase in phosphorylated H3 at low concentrations of 
the inhibitor as Aurora B activity increases in response to Aurora A inhibition. At 
higher concentrations, there is a sudden drop in phosphorylated H3 as Aurora B is 
no longer able to compensate. Aurora A inhibition by MLN8237 causes a G2/M 
arrest in the cell cycle as Aurora A kinase activity is vital for mitosis.31 
The MLN compounds (10, 11) also show a reduction in the levels of MYCN in SK-
N-BE(2) cells, a neuroblastoma cell line with amplified MYCN.37 However, the 
effect on MYCN levels are limited, even at much higher doses than the IC50, 
suggesting that inhibition of the kinase function of Aurora A does not affect the 





myc observed with these compounds is believed to arise either from prolonged 
kinase inhibition or a small change in Aurora A conformation.31 
 
 
Figure 1.12 Structures of MLN series of compounds 
 
MLN8237 (alisertib) (11) was considered promising enough to warrant testing in 
clinical trials and entered a phase I trial for relapsed neuroblastoma patients testing 
the combination of MLN8237 with irinotecan and temozolamide.69 Irinotecan and 
temozolamide were chosen as the regime is generally well-tolerated though 
response rates are very low. MLN8237 has been shown to increase the sensitivity 
of neuroblastoma cells to standard chemotherapies including doxorubicin in vitro. 
However, the combination of MLN8237, irinotecan and temozolamide showed no 
improvement in survival.68 Significant toxicity was also seen, resulting in the need 
to modify the protocol to include myeloid growth factor support.68 Currently, the 
compound (11) is in clinical trials for advanced breast cancer and CNS tumours in 
adults.70 
Alisertib has also been assessed for its effect on other Aurora A-driven cancers. In 
a phase I study of advanced gastrointestinal cancers, alisertib was given along with 
a modified FOLFOX regimen (folinic acid, fluorouracil and oxaliplatin). The 
treatment regime was only tolerated at the lowest dose of alisertib, which only 
achieved a partial response (PR) in one out of fourteen patients involved in the 






In a 2019 phase I trial in combination with pazopanib in advanced solid tumours in 
adults, 15 of 27 patients experienced stable disease (SD) and two achieved PR.72 
Alisertib has been shown to be metabolised by CYP 3A4,73 indicating a potential 
for drug interaction with pazopanib, also metabolised by CYP 3A4.74 Indeed, 
pharmacokinetic analysis showed an increase in alisertib plasma concentration 
when administered with pazopanib.72  
Alisertib has entered clinical trials for many other cancers in combination with many 
other existing regimens (Table 1.4) with limited success. There are still ongoing 
trials to try to find a useful setting for alisertib. 
Table 1.4 Clinical trials using alisertib70, 72,75–82 
NCT 
Identifier 
Target Disease Combination Therapy Outcome 
NCT02114229 
(Phase II)  
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Advanced endocrine-
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patients) 
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NCT01154816 
(Phase II)  
Young patients (<21 
years) with refractory 







(Phase I)  
Relapsed or refractory 
B-cell lymphoma 


































It has been suggested that clinical trials for investigational neuroblastoma 
treatments should be modified in response to the lack of suitable patients 
(generally only relapsed or refractory patients are eligible) and to enable the 
assessment of a treatment’s effect at an earlier stage of disease, as it is especially 
difficult to achieve any response in relapsed neuroblastoma.83 One proposal is to 
identify more groups of high-risk patients to use in clinical trials, including those 
presenting with MYCN amplification, before relapse, with small groups of patients 
each trialling a variation of a new treatment in the hopes of more quickly identifying 







CD532 (12) (Figure 1.13) is a selective Aurora A inhibitor developed by Gustafson 
et al.31 Even at low concentrations of CD532, a loss of N-myc could be detected. 
CD532 inhibits the kinase activity of Aurora A (IC50 = 45 nM), though not as 
potently as MLN8237 (IC50 = 1.2 nM) and does not cause a G2/M cell cycle 
arrest.31 Instead, a G0/G1 arrest is seen, which accompanies the loss of N-myc. 
Furthermore, a nonphosphorylateable N-myc mutant was not degraded to the 
same extent as wild-type N-myc, supporting the idea that phosphorylation of N-myc 
after disruption of the interaction is a key step in N-myc degradation.31,43  
The crystal structure of Aurora A bound to CD532 helps to explain the apparent 
disruption of the Aurora A/N-myc interaction. CD532 binds at the ATP binding site 
and induces a conformational change which appears to affect the binding of N-myc 
to Aurora A. The crystal structure shows a 6.5-7.2 Å shift of 1 and 2, causing a 
twist in the -sheet region (Figure 1.14). There is also a 6.2 Å shift of the -helix 
closest to the -sheet region and a 180º flip of the activation loop. For this reason 
the authors describe CD532 as an “amphosteric” inhibitor, both competing with 
ATP at the ATP-binding site and acting at an allosteric site to disrupt protein-
protein interactions.31  
 
 








Figure 1.14 Aurora A with N-myc (grey, PDB 5G1X), with ADP bound (green 
sticks), overlaid with Aurora A crystallised with CD532 (turquoise and pink 
sticks, PDB 4J8M). Shifts in conformation are shown as measurements.31 
 
There is limited published SAR data for the development of CD532 but published 
data highlight the importance of the trifluoromethyl group (Figure 1.15) for the 
disruption of the Aurora A/N-myc complex. Other groups appear to be important in 







Figure 1.15 The structure of CD532 with groups involved in interaction with Aurora 
A highlighted; the cyclopentyl group (red) sits in a hydrophobic pocket of 
Aurora A; the aminopyrazole-pyrimidine section (green) facilitates binding to 
the ATP binding hinge and the urea feature (blue) interacts with an important 
catalytic residue, Asp274. Finally, the trifluoromethyl (purple) is believed to be 
large enough to displace surrounding chains and trigger a conformational 
change in Aurora A.31 
 
 
Figure 1.16 CD532 (pink sticks) in the ATP binding site of Aurora A; hydrogen 
bonds are shown in black (PDB 4J8M); interacting side chains are labelled 
and shown as sticks; N-myc (orange) is overlaid (from PDB 5G1X) for 
reference 
 
Preclinical trials of CD532 using neuroblastoma xenografts in mice showed a 
decrease in N-myc levels with addition of CD532. The mouse models showed 





Using slowly increasing CD532 concentrations, the extent of the difference 
between CD532 and MLN8237 was measured: CD532 promoted dose-dependent 
loss of the protein-protein interaction, with MLN8237 producing a greatly reduced 
response. CD532 also appears to selectively disrupt the Aurora A/N-myc 
interaction, as the N-myc/MAX binding was not affected.31 
1.6.3 VX-680 
VX-680 (13) (Figure 1.17), developed by Vertex Pharmaceuticals, inhibits all three 
members of the Aurora kinase family with Ki values of 0.6, 18 and 4.6 nM for 
Aurora A, B and C respectively.85 In cell-based assays, VX-680 has been shown to 
inhibit proliferation of tumour cell lines with IC50 values in the range of 15-130 nM.86 
Although VX-680 is not selective for a specific member of the Aurora family, it does 
favour the Aurora family over other, similar kinases, 28 with only FLT3 kinase 
activity inhibited with an IC50 of 30 nM.87 Dual inhibition of the Aurora family and 
FLT3 may even be beneficial in certain cancers, such as Acute Myeloid Leukaemia 
(AML), which can also be driven by FLT3 activity.87 While VX-680 is a potent 
inhibitor of the kinase activity of the Aurora family, it does not affect the interaction 
between Aurora A and N-myc.31 
 
Figure 1.17 Structure of VX-680 
 
In vivo studies showed promising results in mice with human AML xenograft and 
appeared to be well tolerated.85 However the compound did not progress beyond 







 Aims of the Project 
The project aims to identify novel inhibitors of Aurora A which may also be capable 
of disrupting the Aurora A/N-myc complex using several potential target sites 
(Figure 1.18). The sites include the ATP binding pocket, the kinase salt bridge, a 
site directly involved in the Aurora A/N-myc protein-protein interaction and two sites 
identified by the Institute of Cancer Research (ICR). These options will be 










Figure 1.18 The potential target sites for small molecule interaction with Aurora A; 
(A) The crystal structure of Aurora A (grey) and TPX2 (purple) (PDB 5LXM)24 
with N-myc (orange) overlaid from the crystal structure of Aurora A bound to 
N-myc (PDB 5G1X);45 (B) The broken salt bridge between Glu162 and 
Lys181 (pale yellow sticks) from the crystal structure of Aurora A with vNAR-
D01 (PDB 5L8L)48 to stabilise the inactive conformation; (C) Crystal structure 
of Aurora A (grey) interacting with N-myc (orange). Only one of the -helical 
regions of N-myc was present in the crystal structure; (D) The ATP binding 
site of Aurora A with ADP bound (green sticks); (E) Crystal structure of Aurora 
A (grey) and TPX2 (purple) with the fragment MES bound (pink sticks); (F) 
Closer view of TPX2 bound to Aurora A  
 
1.7.1 Salt Bridge Site (Type III) 
The salt bridge formed between residues Lys162 and Glu181 is important for the 
active conformation of Aurora A and in the crystal structures of Aurora A with 
various inhibitors this salt bridge is broken.26, 31, 49–54, 62,67 A compound which 
prevents the formation of the salt bridge might stabilise the inactive conformation of 
Aurora A which may be useful for neuroblastoma treatment and would act as a 
type III kinase inhibitor if it is non-competitive with regard to ATP. Computational 
methods could help to narrow down the search for a starting point here. 
Type III kinase inhibitors are generally believed to be able to achieve greater 
selectivity between kinases as they do not rely on binding at the highly conserved 
ATP binding site.21 This would be a major advantage of pursuing this approach, but 
to answer the question of whether the ATP binding site is more highly conserved 
than the area surrounding the salt bridge, the most similar kinases to Aurora A will 
be analysed for conservation of the surrounding amino acids in an attempt to justify 







1.7.2 ATP Site (Type I) 
The Aurora A ATP binding site is already known to bind small molecules, including 
existing ATP-competitive type I inhibitors such as CD532 (12) (Figure 1.13),31 and 
VX-680 (13) (Figure 1.17). Some of these inhibitors are selective for Aurora A and 
have been shown to induce a conformational change to cause some disruption to 
the Aurora A/N-myc complex. These existing inhibitors could be used as a starting 
point to develop compounds with a greater effect on the Aurora A/N-myc 
interaction, hopefully whilst maintaining the selectivity over other kinases. 
Whilst these existing inhibitors might provide a useful starting point for further 
development, there is some toxicity associated with current ATP-competitive 
Aurora A inhibitors.81 For this reason, and to identify potentially more novel 
compounds, computational methods can be employed to investigate other possible 
starting points for inhibitor design. 
1.7.3 MES Site (Type IV) 
Crystallographic experiments conducted at ICR revealed a fragment (MES, 
morpholino ethanesulfonic acid, (14, Figure 1.20) which appeared to show some 
affinity for the Aurora A/TPX2 complex (Figure 1.18E). This interaction is yet to be 
validated with biophysical data and the importance of this site in disrupting the 
Aurora A/N-myc complex for neuroblastoma treatment remains to be proven. 
However, overlaying N-myc on this crystal structure shows a clash with the MES 
binding pocket (Figure 1.19), indicating N-myc binding may be incompatible with a 
small molecule inhibitor in the MES pocket. Additional crystallographic experiments 
could be supplemented by fragment growth programs (such as SPROUT89 or 
OpenGrowth90) or virtual screening of compound libraries to develop MES into a 






Figure 1.19 Aurora A/TPX2 (grey and purple) crystal structure with MES bound 
(pink sticks). N-myc (orange) is overlaid to demonstrate the clash with MES. 
 
Alternatively, fragment and compound libraries can be screened virtually at the 
same site as MES to look for alternative starting points at this site. The same 
libraries can be analysed for similarity to MES to identify whether any MES-like 
fragments and compounds are predicted to bind strongly at this site. 
 
 









1.7.4 TPX2 Site (Type IV) 
Building from work at the MES site, a key cavity involved in TPX2 binding will be 
explored (Figure 1.21). Fragment and compound libraries will be docked to identify 
those predicted to bind. Fragments from the TPX2 and MES sites could be joined 
in an effort to improve binding strength and selectivity, hoping to induce a 
conformational change to prevent N-myc binding. TPX2 is also involved in 
activation of Aurora A so targeting this interaction could affect the activity of Aurora 
A.47 
 
Figure 1.21 The TPX2 site explored in this project, with MES overlaid for reference 
(pink sticks). The key TPX2 side chains (purple) defining the site are 
highlighted (Trp34 and Phe35). 
 
1.7.5 N-myc Site 
Directly blocking the protein-protein interaction at the N-myc site might be possible 
in a number of ways. First, Trp77 of the -helix appears to sit in a shallow cavity in 
the crystal structure and binds to Aurora A via both hydrophobic and H-bond 





pocket for small molecules, docking of fragment and small molecule libraries may 
provide an idea of the viability of the development of direct Aurora A/N-myc 
interaction inhibitors. The shallow Trp77 binding pocket can be analysed by 
SiteMap91 to provide an idea of how likely this site might be to accommodate a 
small molecule. In addition, successful soaking of fragments and small molecules 
into Aurora A crystals could give further support of this approach. 
A second strategy could be to design a mimetic of the -helix based on the key 
residues of N-myc which interact with Aurora A. A rigid scaffold supporting 
structures similar to the important side chains could provide good selectivity and 
promote N-myc degradation by preventing binding to Aurora A.92–94  
The crystallised N-myc peptide could also be used as a basis to search within 
compound libraries for anything with some similarity to the key N-myc side chains. 
Alternatively, curated peptidomimetic libraries, such as the Enamine -helix 
mimetic library,95 could be virtually screened against the Aurora A crystal structure 
to help in the selection of compounds which may interact with Aurora A in this area. 
1.7.6 Identifying Compounds 
Where possible, virtual screening conditions for each site were validated by 
redocking co-crystallised ligands into their crystal structures to provide confidence 
in docking results. Docking was performed using Glide96 (Schrödinger), alongside 
which a prediction of “druggability” at each site by small molecules was obtained 
using SiteMap91 assessment (Schrödinger). Various virtual libraries were screened 
at different sites, including diversity-oriented,97 fragment98,99 and peptidomimetic 
libraries.95,100  
Where appropriate, other computational methods were used, for example ROCS 
(Rapid Overlay of Chemical Structures) screening of crystallised molecules to 
identify compounds within screening libraries with similar shapes and electronics. 
Alternatively, fragment growth programs such as SPROUT89 were used to explore 





Computational work guided the selection of sets of compounds to test in vitro, with 
these results providing further validation of the docking models, which helped 
inform iterative cycles of virtual and in vitro testing. One possible workflow is shown 
(Figure 1.22). 
 
Figure 1.22 The potential workflow for any hits found through virtual screening 
 
High throughput crystal soaking used Aurora A crystals, possibly prepared in 
complexes with other binding partners (for example vNAR-D01), into which many 
possible inhibitors can be soaked and analysed using X-Ray crystallography to 
identify compounds which bind to Aurora A in the expected binding sites. The 
availability of each site for soaking in fragments is affected by crystal packing and 
the conformation of the protein.  
For example, the crystal packing arrangement with Aurora A alone exposes the 
face required to probe the TPX2 binding site, but obscures the N-myc binding site. 
When Aurora A is co-crystallised with TPX2 the crystal packing is altered to expose 
the N-myc binding site. This co-crystal structure also creates the MES binding site. 
Co-crystallising Aurora A with vNAR-D01 stabilises the inactive conformation of the 
kinase with the salt bridge broken and available for crystal soaking. 
Crystallography experiments would give information about the binding pose of 
fragments, but would not reveal the effects of fragments and small molecules on 
the kinase activity of Aurora A. To probe this second question, the Caliper mobility 
shift assay101 was used to quantify Aurora A kinase inhibition. This could be used 
either to screen large numbers of compounds at a single concentration or to 
generate IC50 values of individual molecules. The assay can also be used to 
determine whether compounds compete for binding with ATP, which will be 













To explore the question of whether compounds disrupt the Aurora A/N-myc 
protein-protein interaction, previous work has made use of fluorescence 
polarisation assays45 to assess the effect of CD532 and other type I inhibitors of 
Aurora A on the Aurora A/N-myc interaction. AlphaScreen has also been explored, 
which uses singlet oxygen to detect the presence or absence of an interaction 
between two entities.102 In this case, the effect of the addition of small molecules 
on the extent of Aurora A/N-myc interaction could be observed. Finally, Kd values 
can be calculated using NMR experiments, including STD-NMR. Some work was in 






Chapter 2 N-Myc Site 
Perhaps the most direct method of blocking the interaction between Aurora A and 
N-myc would be to use a competitive inhibitor of N-myc which binds in the same 
region as the helical portion of N-myc. A competitive inhibitor used in this way 
could destabilise the interaction, which would result in the Fbxw7-mediated 
degradation of N-myc.103 This approach might be achieved through traditional 
small molecule inhibition or from a designed -helix mimetic. 
Studies suggest the Aurora A Interaction Region (AIR), the key section of N-myc 
which are responsible for Aurora A binding is between residues 28-89. The Aurora 
A/N-myc crystal structure used for docking (PDB 5G1X) contains only part of this 
region (residues 61-89), but this has been shown to be sufficient for binding to 
Aurora A, albeit with a lower binding affinity than the full AIR.45  
 Binding Site Analysis 
Visual inspection of the Aurora A/N-myc interaction interface indicated the three 
key residues of the N-myc -helix involved in binding to Aurora A were Trp77, 
Met81 and Glu84, which correspond to the i, i+4, and i+7 side chains which project 
in the same direction from an -helix (Figure 2.1). Trp77 appeared to sit in the 
most promising looking potential binding site for small molecule of the three side 







Figure 2.1 Predicted interactions between Aurora A (grey) and N-myc (orange) 
(PDB 5G1X)45 
 
To add to the visual inspection of this area, a prediction of the “druggability” of the 
Trp77 binding pocket was generated using SiteMap (Schrödinger).91 SiteMap 
analyses potential binding sites by using “site points” spaced 1 nm apart within the 
binding area. Each site point is analysed for its potential to be involved in 
interaction with a ligand, by assessing properties such as the exposure to solvent 
and proximity to the protein. Site points which could contribute to binding can be 
linked together to highlight a potential binding site.104 
SiteMap also generates a SiteScore based on this analysis. SiteScores are 
calculated by taking into account the size of the site, depth of the pocket, hydrogen 
bond formation capability and the balance between hydrophobic and hydrophilic 
regions,104 incorporated into the equation: 
𝑆𝑖𝑡𝑒𝑆𝑐𝑜𝑟𝑒 = 0.0733√𝑛 + 0.6688𝑒 − 0.20𝑝 
Where 𝑛 is the size (number of site points), 𝑒 is the overall score for solvent 





avoid very high scores for the most polar sites. A SiteScore above 0.8 indicates the 
area is a binding site for small molecules, whilst a SiteScore below 0.8 means the 
site is unlikely to bind ligands.91 
A second score, the Dscore or “druggability” score which is designed to focus on 
the ability of the site to bind a drug-like ligand, as opposed to any kind of small 
molecule. The Dscore is calculated in a similar way to the SiteScore, with the main 
difference of the removal of the limit on the hydrophilicity value. This means the 
requirement for highly charged ligands to bind highly charged sites, which may be 
unfavourable drugs, is penalised. The Dscore equation is: 
𝐷𝑠𝑐𝑜𝑟𝑒 = 0.094√𝑛 + 0.60𝑒 − 0.324𝑝 
Where 𝑛, 𝑒 and 𝑝 each take the same properties as SiteScore.91 In the case of 
Dscore, a value above 0.98 is “druggable”, 0.83-0.98 means a site is “difficult” and 
below 0.83 is “undruggable”.91  
Analysis of the Trp77 binding site by SiteMap from the Aurora A/N-myc crystal 
structure (PDB 5G1X) calculated SiteScores of 0.525 and 0.536 with and without 
water, respectively. These scores are both much lower than the minimum score of 
0.8 for a “druggable” binding site suggested by Schrödinger. Dscores were 
similarly disappointing, at 0.457 and 0.502 with and without water, again much 
lower than even the “difficult” druggability score of 0.83. 
 Docking 
Despite the low scores from computational binding site analysis, libraries of 
compounds were screened virtually to further explore the feasibility of using small 
molecule inhibitors to directly block the Aurora A/N-myc interaction (Table 2.1). The 
docking libraries used in the project included fragment libraries (Asinex99, Bionet98 
and Maybridge), larger compound libraries with a focus on diversity (MCCB and 
Chembridge97) and -helix mimetic libraries (Enamine95 and ChemDiv100, used 






Especially for the -helix mimetic libraries, the goal would be to mimic the three 
amino acid side chains of N-myc which project towards and interact with Aurora A. 
In the case of N-myc those side chains are Trp77, Met81 and Glu84, making up 
the i, i+4, and i+7 side chains which project in the same direction from an -helix 
(Figure 2.1). Currently, no helical peptide based inhibitor of the Aurora A/N-myc 
protein-protein interaction has been reported in the literature. 
Table 2.1 Compound libraries used for virtual screening 
Library Library Type Number of 
Compounds (approx.) 
Asinex99 Fragments 21000 
Bionet98 Fragments 1100 
Maybridge Fragments 1000 
MCCB Drug-like compounds 30 000 
Chembridge DIVERSet97 Diversity 100 000 
Enamine95 -helix mimetics 14 000 
ChemDiv100 Peptidomimetics 14 000 
 
At the N-myc site libraries of compounds were first docked using Glide 
(Schrödinger) with the coordinates of Trp77 as the centre point for docking grid 
generation, both with and without crystallised water molecules. All seven 
compound libraries were screened using this docking grid. Docking results were 
ranked by Glide score, which takes into account properties including hydrogen 
bonding, distances between ligand and receptor and bond angles. The ranked 
compounds were then filtered to remove any PAINs scaffolds. These included 
Michael acceptors, quinones, rhodanines, and others mentioned in the literature 






Figure 2.2 Some of the PAINs structures from docking results 
2.2.1 Trp77 Grid Centre 
With the water molecules included, a good proportion of fragments appeared to 
show good overlap with the Trp77 side chain and mimicked the hydrogen bond 
interaction identified between the tryptophan side chain and the carbonyl of Gly291 
of Aurora A. A number of fragments were also predicted to form hydrogen bonding 
interactions with the backbone of Leu293 (Figure 2.3).  
 
Figure 2.3 A fragment from the Maybridge library (compound ID CC31304) 
showing a docking pose with some overlap with the Trp77 side chain of N-
myc (orange) and predicted hydrogen bonding interaction with Leu293 of 
Aurora A (grey, PDB 5G1X) 
 
Without crystallised water molecules in the docking grid, fragments were able to 
dock in positions closer to the ATP binding site, often with predicted interactions 





docking conditions, Glide scores were much higher, a possibly unsurprising result 
considering the predictions from the docking poses of more hydrogen bonding 
interactions between high-scoring fragments and Aurora A amino acids. 
Unfortunately, with the crystallised water excluded, fragments were not predicted to 
overlap with the key side chains of N-myc. 
 
Figure 2.4 One of the highest ranked fragments by Glide score (compound ID BAS 
00368055, Asinex) using the Trp77-centred Glide grid, showing predicted 
interactions with Mg2+ ions (green cross) with N-myc shown (orange, PDB 
5G1X) 
 
Larger compounds docked using N-myc Trp77 as the docking grid centre tended to 





site, as opposed to the desired mimicking of the N-myc helix side chains. This 
result was observed regardless of the presence or absence of crystallised water. 
As with the fragment libraries, docking the larger compound libraries with a Trp77 
grid centre also generated predicted poses in which there was often a good 
overlap between the aromatic side chain of Trp77 and an aromatic ring in the 
docked compounds. Unfortunately, no compounds were predicted to mirror all 
three of the desired N-myc helix side chains (Figure 2.5). A few compounds were 
also predicted to reach into the kinase substrate binding site, providing another 




Figure 2.5 A docking pose of a compound (compound ID ALB-H01519346, MCCB) 
from docking drug-like compounds showing good overlap with the Trp77 side 
chain of N-myc (orange, PDB 5G1X). Aurora A side chains predicted to form 







Figure 2.6 One of the larger compounds (compound ID 9107029, MCCB) 
predicted to extend towards the substrate binding region of Aurora A (grey, 
PDB 5G1X). Aurora A side chain predicted to form interactions with the 
compound are labelled. 
 
The final commercial libraries docked at this site were made up of larger 
compounds with the potential to act as peptidomimetics. An -helix mimetic of N-
myc would be designed to mimic the positions and interactions of the side chains 
Trp77, Met81 and Glu84 as i, i+4 and i+7 positions of an -helix. Screening 
libraries containing compounds selected for helix mimetic properties were docked 
in the same way as the previous compound libraries, using Trp77 as the centre 
point for generation of the docking grid. The size of the grid was checked to ensure 
the whole of the N-myc helix was included. 
A similar pattern of results was seen with these compounds as was seen for other 
libraries using Trp77 as the grid centre. These compounds were not predicted to 
mimic the three key N-myc side chains. At best, a small number showed some 





with other virtual screens at this site, many compounds extended towards the ATP 










Figure 2.7 Docking results using peptidomimetic compound libraries using the 
Trp77-centred Glide grid; (A) One of the docking poses (compound ID Z250-
1612, ChemDiv) with some overlap with N-myc side chains Trp77 and Met81 
(orange); (B) The more common type of pose generated from these libraries, 
showing one compound (ID Z1757451390, Enamine)extending towards the 
ATP binding site of Aurora A (grey, PDB 5G1X). Amino acids predicted to 
form interactions with the compounds are labelled. 
 
With the exclusion of crystallised water, fewer compounds showed any overlap 
with the side chains of N-myc. Instead, as seen with fragment libraries, compounds 
seemed to favour binding close to the ATP binding site, often predicting 
interactions with magnesium ions and surrounding residues and generating higher 
Glide scores. 
Using Trp77 as the centre point for grid generation in the hope of finding 
compounds which mimic N-myc interactions meant the dimensions of the grid had 
to be large enough to encompass the whole of the helix. With Trp77 as the centre 
point, this meant the grid also extended to cover a portion of the ATP binding site. 
If the centre of the docking grid was changed to Met81, the second of the key N-
myc residues, the docking grid dimensions could be altered in the hope of avoiding 
the generation of poses extending towards the ATP binding site and improving the 
chances of finding compounds which overlap with the helix side chains as desired. 
2.2.2 Met81 Grid Centre 
The helix mimetic libraries were docked using the Met81-centred docking grid, a 
total of 28000 compounds. With Met81 as the docking grid centre compounds were 
again predicted to approach the ATP binding site. However, in contrast to using the 
Trp77 centre, more compounds were predicted to overlap with one or two of the 
three target residues, usually Trp77 and Met81 (Figure 2.8). Unfortunately, no 






Figure 2.8 A docking pose from the peptidomimetic libraries (compound ID G389-
1190, ChemDiv) using a Met81-centred Glide grid with N-myc overlaid 
(orange, PDB 5G1X), showing some overlap with the N-myc side chains 
Trp77 and Met81. Aurora A residues predicted to form interactions with the 
compound are labelled (grey sticks). 
 
Moving the grid centre to Met81 did improve the proportion of top results following 
the N-myc helix but did not completely overcome the problem of compounds 
extending in the direction of the ATP binding site, especially with the removal of 
crystallised water (Figure 2.9). Reassuringly, Glide scores of the top results were 
not greatly affected by the change of grid (remaining roughly between -6.5 and -7.0 
with water). To further explore the effect of changing the grid centre and avoiding 





were altered once more, using Glu84 as the centre point, even further from the 
ATP binding site. 
 
Figure 2.9 Docking peptidomimetic compounds with the Met81-centred Glide grid 
without water often generated poses in which compounds extended away 
from the N-myc helix (orange, PDB 5G1X) and towards the ATP binding site 
(compound ID Z352538160, Enamine). Interacting side chains of Aurora A 
(grey) are labelled. 
 
2.2.3 Glu84 Grid Centre 
In an attempt to minimise the number of compounds attempting to bind in the ATP 





with all three target side chains, Glu84 was used as the centre point for the docking 
grid. Glu84 is at the end of the N-myc -helix, furthest from the ATP binding site, 
so the docking grid could cover the N-myc helix without reaching towards the ATP 
binding site. The two peptidomimetic libraries were screened at this site, a total of 
28000 compounds. 
This approach was successful in reducing the proportion of compounds extending 
towards the ATP binding site but again did not identify any compounds predicted to 
mimic all three key N-myc side chains. Instead, with a Glu84 grid centre more 
compounds were predicted to reach into the kinase substrate binding site than 






Figure 2.10 Docking results at the N-myc site with Glu84 grid centre; (A) The 
second result from the ChemDiv helix mimetic library (pink sticks, Glide score 
-5.403, ID F594-0384) docked with water using with N-myc (orange) overlaid 
from the Aurora A/N-myc crystal structure (PDB 5G1X); (B) Rotated view of 
the same docking result; the compound is predicted to extend over the ridge 






In addition, Glide scores were also much lower under these conditions, with the 
highest score at only -5.625. Using Glu84 as the centre point did not give the kind 
of docking results hoped for with commercial peptidomimetic libraries. An 
alternative option could be to use designed helix mimetics based more specifically 
on the N-myc helix in particular. 
 
2.2.4 Helix Mimetic Scaffolds 
Published helix mimetic scaffolds in which the required side chains of an -helix 
mimetic can replace specific R groups of a designed core (Figure 2.11) were also 
docked using each of the target side chains as the centre point for docking in the 
hope of finding a scaffold predicted to bind in the same orientation as the side 
chains of N-myc. A bespoke virtual library was designed for this purpose, using the 







Figure 2.11 Helix mimetic scaffolds used; the groups R1, R2 and R3 were replaced 
with the side chains of Trp77, Met81 and Glu84, respectively 
 
As with the previously discussed docking experiments, each of the three side 
chains were used as the centre point for grid generation, resulting in three sets of 
docking results. Each set of compounds was also screened with and without 
crystallised water molecules. 
With the Trp77-centred grid, some good overlap with the Trp77 side chain was 
observed, especially in the absence of crystallised water, along with some good 
Glide scores (between -6.3 and -9.5) for the top results. Unfortunately, these high 
scores were based on poses in which the compounds extended towards the ATP 





(Figure 2.12). As seen with other screens at this site, the problem was worse with 
the removal of crystallised water, and these poses also gave the highest Glide 
scores.  
 
Figure 2.12 One of the highest ranked results (by Glide score) of the set of 
designed helix mimetic compounds docked with a Trp77 grid centre, showing 
the compounds extending towards the ATP binding site. Interacting side 
chains of Aurora A (grey) are labelled. 
 
Moving along the helix and using Met81 as the grid centre produced the same 
problems observed with the Trp77 grid; the top results all extended towards the 
ATP binding site. Some aromatic rings were predicted to overlap with the aromatic 
Trp77 side chain, but the tryptophan side chain added to designed scaffolds did not 






Figure 2.13 Helix mimetic scaffold docking using Met81 as the grid centre. The N-
myc Trp77 side chain (orange, PDB 5G1X) often showed some overlap with 
aromatic rings from the designed compounds, but this was not with the 
intended tryptophan-like portion of the designed compound. Predicted 
interacting amino acids of Aurora A (grey) are labelled. 
 
To complete the docking set, the library of designed scaffolds was also screened 
virtually against the Glu84-centred grid. Again, no compounds were predicted to 
mimic all three key side chain of N-myc, although there was a pronounced 





Instead, docking poses showed hydrogen bonding interactions with a variety of 
other Aurora A residues not seen with previous virtual screens (e.g. K339), but this 
was accompanied by a significant worsening of Glide scores associated with these 
poses (Figure 2.14).  
 
Figure 2.14 N-myc Glu84-centred docking results from designed helix mimetics, 
showing a lack of cover of the three key N-myc side chains (orange) and 
lower Glide scores than other virtual screening conditions 
 
Most compounds were not predicted to mimic the side chains and Glide scores 
were generally much lower for these compounds than for the helix mimetic 
libraries. The compound closest to overlapping with all three target residues is 
shown (Error! Reference source not found.). Given the poor predictions from 








Figure 2.15 Docking of helix mimetic scaffolds at the N-myc site; the 20th result by 
Glide score (pink sticks, Glide score -3.110) from the library of designed helix 
mimetics docked at the N-myc site without water with Met81 as the centre 
point for grid generation 
 ROCS 
The ligand-based design tool ROCS (Rapid Overlay of Chemical Structures) was 
used to complement the identification of -helix mimetic inhibitors at the N-myc site 
found by Glide docking. ROCS can be used to identify compounds in a given 
library which have a similar 3D shape to a known ligand. 
In a ROCS screen to search for compounds within the Enamine -helix mimetic 
library with a similar shape to the N-myc helix (residues 77-84), a number of 
compounds were identified which closely matched two of the three target residues, 
usually Trp77 and Glu84, but none were found which matched all three side chains 






Figure 2.16 The core N-myc helix used for ROCS screening with distances shown 
in Å and the three key side chains highlighted 
 
Many compounds overlapped with only one of the target residues and overlaid with 
sections of the backbone instead of the key side chains. To avoid these kinds of 
compounds dominating the top ROCS results, a second ROCS screen was 
performed using only the desired side chains. The distances between each side 
chain from the crystallised N-myc helix were measured and the side chains alone 
were used, connected by carbon chains the right length to give similar distances 
between groups as the crystal structure.  
The ROCS screen based on this structure was more successful in finding 
compounds which favoured following the side chains over the backbone. 
Unfortunately, as with the previous screen, compounds overlaid well with only two 
of the side chains at most, with the majority of compounds overlapping with only 






Targeting the N-myc binding site would be the most direct way to prevent formation 
of the Aurora A/N-myc protein-protein interaction. However, analysis of the binding 
site did not support this region as a binding site for small molecules. Docking 
results from the screening of commercial compound libraries supported the site 
analysis, with low Glide scores and unconvincing docking poses. Designed 
mimetics of the N-myc helix could be a route to disrupting the protein-protein 
interaction, but the predicted binding poses generated did not predict these 
compounds would occupy the same space as the N-myc helix. Overall, whilst the 
directness of this approach was appealing, the discouraging computational 
predictions resulted in this approach being set aside to allow greater focus on other 





Chapter 3 Type IV Inhibition 
Interaction with TPX2 helps to activate Aurora A and trigger mitosis so targeting 
this site could prevent Aurora A activation. The TPX2 site is defined by the 
residues Trp34 and Phe35 of TPX2 (Figure 1.21). TPX2 is a substrate and 
activator of Aurora A. By preventing the activation of Aurora A by TPX2 using small 
molecule inhibitors binding in the cavity defined by Trp34 and Phe35, the effect of 
Aurora A kinase activity in cancer could be avoided.30 This would be especially 
useful in cancers presenting with Aurora A overexpression.29,43 Furthermore, 
preventing the activation of Aurora A by TPX2 could contribute to an inactive 
conformation of Aurora A which is incompatible with N-myc binding,47 subsequently 
leading to N-myc degradation and cell death in neuroblastoma.45  
Previous crystallography experiments yielded MES, a fragment seen to bind at the 
interface of Aurora A and TPX2 in a co-crystal structure (Figure 1.21). Overlaying 
N-myc from the Aurora A/N-myc co-crystal structure45 indicates a clash between 
MES and N-myc (Figure 1.19). It might be possible to develop MES into a 
compound capable of disrupting the Aurora A/N-myc protein-protein interaction.  
 Binding Site Analysis 
SiteMap analysis of the TPX2 site, using the co-ordinates of the side chains Trp34 
and Phe35 from the Aurora A/TPX2 crystal structure (PDB 5LXM) gave a 
SiteScore of 0.708 with water and 0.573 without water. Like the Trp77 site, these 
scores were lower than the “druggable” score of 0.8.91 
At the MES binding site, crystallised MES was used to identify the site in the 
Aurora A/TPX2 crystal structure, generating SiteScores of 0.828 and 0.798 with 
and without crystallised water molecules. These scores provided further hope that 
the MES binding site was “druggable” and it may be possible to develop small 







Compound and fragment libraries were docked at the TPX2 binding site using the 
centre of two Aurora A residues (His187 and His280) as the centre point for virtual 
screening. The key TPX2 residues (Trp34 and Phe35) lie between these two 
histidines in the Aurora A/TPX2 crystal structure (Figure 3.1). For all TPX2 site 
screens the Aurora A/N-myc crystal structure (PDB 5G1X) was used with N-myc 
removed. Three fragment libraries and two drug-like compound libraries were 
docked at this site, a total of around 152 000 compounds. 
 
Figure 3.1 The TPX2 binding site: TPX2 residues used to define the site (yellow 
sticks) with MES (pink sticks) shown for reference and the two Aurora A 
histidines used as a centre point for docking highlighted (grey sticks, labelled) 
 
A large number of compounds contained cyclic regions (often aromatic) which 
were predicted to sit in between His187 and His280 and may show opportunities 





MES binding site, with a large number of diverse compounds from the MCCB 






Figure 3.2 Library docking at the TPX2 site without water with MES overlaid as 
pink sticks; (A) The top result from the MCCB library (green sticks, docking 
score -6.533, ID ALB-H10304495) is shown reaching from the TPX2 site into 
the MES site; (B) The top result from the Asinex fragment library (orange 
sticks, docking score -6.757, ID BAS02937058) is shown extending from the 






Docking was also performed using MES as the centre point for grid generation. 
With crystallised water included many hydrogen bonding interactions to water were 
predicted, in both fragment and drug-like compound libraries (Figure 3.3).  
 
Figure 3.3 Docking at the MES binding site with water, showing predicted 
hydrogen bonding interactions with water molecules (red crosses) and TPX2 
(yellow); (A) Fragment library result (ID B05437278, Asinex); (B) Drug-like 
compound library result (ID 9041792, MCCB) 
 
With water excluded, more direct interactions with the side chains of both Aurora A 
and TPX2 were predicted (Figure 3.4). A set of 125 of the most interesting docking 
results were collected from in-house and commercial libraries and prepared for 






Figure 3.4 Docking at the MES binding site without water, showing predicted 
hydrogen bonding interactions to labelled side chains of Aurora A (grey) and 
TPX2 (yellow); (A) Fragment library result (ID PS-3756, Bionet); (B) Drug-like 
compound library result (ID 4333-1690, MCCB) 
 
Finally, a library of compounds based on the structure of MES was created from 
commercial and designed compounds and screened in silico (Appendix 1). This 
library was derived from a combination of searches within commercial databases 
for structural similarity to MES and designed compounds with small structural 
changes to MES, such as changes in the ring size and changes to the sulfonic acid 
group. Many of these compounds generated docking poses which appeared similar 
to the docking pose of MES in its crystal structure and the predicted interactions of 
these designed compounds mirrored the kinds of interactions predicted for the 










Figure 3.5 The top three results (by Glide score) from the designed MES-based 
library without water. Predicted interacting residues are labelled on Aurora A 
(grey) and TPX2 (yellow) 
 
 SPROUT 
The fragment growth program SPROUT was used to try to improve the crystallised 
MES fragment. SPROUT uses a crystal structure of the target protein and identifies 
hydrogen bond donors, acceptors, and hydrophobic regions. Specific regions can 
then be chosen to extend towards by selecting potential interacting groups (e.g. 
hydrogen bond donors to interact with a hydrogen bond acceptor on the protein) 
and a selection of linking groups to connect the fragment to the new interacting 
group to generate a “tree” of possible extended fragments. After repeating this 
process multiple times, a “forest” of possibilities can be established from multiple 
“trees”.  
In the case of MES, the crystallised fragment failed to grow towards any chosen 
regions without rotating the predicted binding position of the MES portion. When 
MES was restricted to remain in its crystal pose, it failed to produce options for 
growing the fragment. The sulfonic acid group was also removed in an attempt to 
find possible alternative group in this position (Figure 3.6). Similar problems were 






Figure 3.6 SPROUT setup, with a starting fragment shown in the binding site (blue 
lines) 
 Crystallography 
A set of 125 of the most promising docking results were selected and sent to be 
soaked into Aurora A crystals for x-ray crystallography, performed by Patrick 
McIntyre of the Bayliss group. Compounds were selected based on a combination 
of Glide score, predicted interactions with the protein and predicted binding poses. 
Of these 125, only seven resulted in a crystal structure with a fragment clearly 
bound anywhere on Aurora A. Unfortunately, none of these compounds matched 
the binding prediction from Glide and did not bind at any of the sites of interest in 
the project.  
Table 3.1 Compound details for the seven fragments present in the Aurora A 
crystal structure 





















Similarly to targeting the N-myc binding site directly, this type IV approach to 
Aurora A kinase inhibition did not provide a convincing starting point for further 
development. Crystallography experiments failed to show any of the chosen 
compounds binding in the predicted positions. Although further investigation into 
these results could be interesting, the focus of the project began to narrow at this 





Chapter 4 Type I Inhibition 
A small molecule inhibitor at the ATP binding site would inhibit the kinase activity of 
Aurora A. As seen with CD532 (12, Figure 1.13), a compound binding at the ATP 
site can also produce a shift in the protein to disrupt the Aurora A/N-myc 
interaction.31 These would be type I kinase inhibitors and could be developed from 
existing inhibitors of Aurora A of this type, or de novo using high throughput or 
virtual screening of fragments or small drug-like molecules. 
 Binding Site Analysis 
Analysis by SiteMap of the ATP binding pocket from the Aurora A/N-myc crystal 
structure (PDB 5G1X) gave SiteScores of 1.14 and 1.08 with and without water, 
respectively. These were the best Sitemap results of all the target sites, indicating 
this is the “most druggable” of the five identified sites discussed in this report, an 
unsurprising result since this pocket is already known to interact well with the small 
molecule ADP and existing type I kinase inhibitors. The difference in the score 
between the inclusion and exclusion of water could be due to the potential for 
making additional water-mediated interactions between the protein and an inhibitor. 
 Development of Existing Inhibitors 
VX-680 (13) and CD532 (12) are existing type I ATP-competitive inhibitors of 
Aurora A. Both inhibitors contain the same hinge binding region so could be 
combined to form a hybrid (Figure 4.1) with the hope that the designed hybrid 
might combine the beneficial features of each. CD532 is a potent and selective 
Aurora A inhibitor, but has shown toxicity and solubility issues. However, CD532 
does have a disrupting effect on the Aurora A/N-myc protein-protein interaction, 
with the Aurora A/CD532 crystal structure suggesting the large trifluoromethyl 
group may be instrumental in this disruptive effect.31 This group is not present in 





By keeping the trifluoromethyl group of CD532, which appeared to be important for 
disrupting the Aurora A/N-myc interaction by SAR,31 the hybrid compound would 
hopefully retain the ability to disrupt the protein-protein interaction.  
  
Figure 4.1 CD532, VX-680 and the designed hybrid: the hinge binding region (red) 
is common to both CD532 and VX-680; urea moiety is from CD532 (blue) and 
methylpiperazine group is from VX-680 (black) 
 
Incorporating the protonatable amine from the methylpiperazine group of VX-680, 
hopefully the solubility of the new hybrid would improve without compromising 
potency. The designed hybrid would offer a structurally novel class of compounds, 






Figure 4.2 Planned CD532/VX-680 hybrid compound template 
 
Synthesis of the hybrid compound was adapted from a literature procedure109 
(Scheme 1). The thiopyrimidine (16) was oxidised with mCPBA to give the sulfone 
(17) in good yield which was then able to undergo SNAr substitution at the 2-
position to generate the substituted pyrimidine (18a-c). Further nucleophilic 
aromatic substitution with 3-amino-5-methylpyrazole and N-methylpiperazine at the 
4- and 6- positions produced the substituted pyrimidine (19a-c) in good yield. The 
pyrazole nitrogen was then Boc-protected (20a-c), followed by reduction of the 
nitro group to the amine (21a-c). The amine was then reacted with the 
corresponding isocyanate to form the urea moiety and deprotection of the pyrazole 
nitrogen yielded the desired compounds (15a-c), which were tested for kinase 














Table 4.1 Summary of final compounds and individual yields for final step 
Compound X R Yield for final 
step 
15a O CF3 79% 
15b S Me 33% 
15c S OMe 36% 
 
 Docking 
4.3.1 Screening Libraries 
As a complementary approach to the development of ATP-competitive compounds 
based on existing inhibitors, both fragment and larger compound libraries were 
docked at the ATP binding site using the co-ordinates of crystallised ADP as the 
docking grid centre point. Although this was not the main focus for work at the ATP 
site, any promising results from this docking could generate new scaffolds for the 
development of ATP-competitive inhibitors which disrupt the Aurora A/N-myc 
interaction, similar to CD532 (12). Docking results may also help to identify 
interactions predicted to be important at this site. 
ADP was redocked in both the Aurora A/N-myc (PDB 5G1X) and Aurora A/TPX2 
(PDB 5LXM) crystal structures. The Aurora A/N-myc structure gave a much better 
RMSD value (0.41 Å versus 2.40 Å) for redocked ADP under SP conditions and 
was, therefore, used for screening libraries. Although XP (extra precision) docking 
did give a better RMSD for both crystal structures, XP docking did take significantly 
more time. The SP RMSD value of 0.41 Å was considered sufficiently low to be 
able to give useful predictions from screening libraries. The 152 000 compounds 
from fragment and drug-like compounds were docked at this site, both with and 





Docking with the crystallised water molecules in place did result in a number of 
predicted water-mediated interactions, providing support for the higher druggability 
score from SiteMap with water included. However, docking scores for both the 
fragment and drug-like compound libraries were similar regardless of whether 
water was included or not, suggesting these additional water-mediated interactions 
were not predicted to produce significantly more favourable binding. 
The fragment libraries tended to produce poses which overlapped with where the 
adenine portion of ADP would sit. Lys162 and Lys143 were popular Aurora A side 
chains with predicted interactions to fragments, often a carboxylic acid. Without the 
presence of water molecules, the highest scored fragments showed only these 
lysine-carboxylic acid interactions and some charge-charge interactions between 
the same carboxylic acid and a magnesium ion (Figure 4.3). Lower ranked 
fragments did show greater variability in the interactions predicted without water, 
with hydrogen bonding predicted to Ala213, Arg220, Glu260, Asn261 or the key 
enzymatic residue Asp274, but none approached the number of interactions shown 






Figure 4.3 Fragment docking results at the ATP binding site without water; (A) One 
of the highest ranked results (by Glide score), showing the fragment 
positioned in the ATP binding site and interactions to a magnesium ion and a 
lysine side chain (compound ID 12N-508S, Bionet), as was seen for many of 
the top results; (B) One of the slightly lower ranked results predicting 








Figure 4.4 Crystallised ADP in its binding site with N-myc (orange) shown (PDB 
5G1X) with water removed 
 
With the crystallised water included, direct hydrogen bonds were predicted almost 
exclusively to Lys143 and Lys162 among the highest scoring fragments (Figure 







Figure 4.5 Docking results at the ATP binding site with water included, showing 
predicted interactions with (A) Lys162 (compound ID 2M-936, Bionet) and (B) 
Lys143 (compound ID 7X-0811, Bionet), along with predicted hydrogen 
bonding to water (red cross) and interactions with a magnesium ion (green 
cross) 
 
For the libraries made up of larger, more drug-like compounds, again the vast 
majority of the highest ranked compounds were predicted to overlap with where 
ADP would be found. There were a few similarities between these libraries and 
fragment libraries, notably the recurrence of interactions with Lys143 and Lys162 
and a carboxylic acid regardless of whether crystallised water was included or not 
(Error! Reference source not found.). With the inclusion of water, the highest 
scoring results all showed some hydrogen bonding interactions with the 
surrounding water molecules, although these additional interactions did not affect 






Figure 4.6 Docking results from drug-like libraries screened at the ATP binding 
site; (A) with water (compound ID ALB-H04810563, MCCB); (B) without water 
(compound ID 9199753, MCCB) 
 
One difference between fragment libraries and these drug-like libraries was the 
predicted pose of many results. Whereas for the fragment libraries a number of 
highly ranked compounds were predicted to interact with the common lysine side 
chains and moved away from the hinge, the larger compounds in the MCCB and 
Chembridge libraries allowed compounds to both form predicted interactions with 
the favoured lysine residues whilst also extending towards the hinge. A few of the 
highest ranking compounds showed predicted hydrogen bonding to key hinge 
residues including Ala213 (Figure 4.7), as opposed to fragment libraries where only 






Figure 4.7 One of the top results from docking the drug-like libraries at the ATP 
binding site, showing predicted hydrogen bonding interactions to Ala213 
(compound ID omega_86847, Chembridge) 
 
These virtual screening results have given some potential ideas for investigating 
new type I kinase inhibitors of Aurora A which could be further explored using 
enzyme activity assays or protein crystallography. 
4.3.2 Designed CD532/VX680 Hybrid Compounds 
The existence of a good quality crystal structure of Aurora A with CD532 bound31 
presented the opportunity to explore the docking poses of CD532/VX680 hybrid 
compounds. CD532 was first re-docked into its binding site until conditions were 
found which produced a re-docked pose similar to that observed in the crystal 
(RMSD 0.53 Å). The optimum conditions for re-docking CD532 were found using 
crystallised CD532 as the grid centre point under SP (standard precision) with a 
Glide grid consisting of a 10 Å inner box and 24 Å outer box. A selection of hybrid 





compounds were docked with and without the cyclopentyl group of CD532 with the 
hope of exploring the role of this group in hybrid compounds. 
Some compounds produced poses which overlaid well with CD532 (Figure 4.8) 
with the additional piperazine ring from VX-680 predicted to be directed towards 
solvent. Unfortunately, this was not the case for the majority of compounds docked. 
In most cases, the docked compounds were “flipped,” with the cyclopentyl region 
directed towards solvent and the piperazine group towards the back of the pocket, 
overlapping with the position of the CD532 cyclopentyl group.  
 
Figure 4.8 The docking pose produced for one of the designed compounds (blue) 
with crystallised CD532 overlaid (pink) (PDB 4J8M). Aurora A side chains 
predicted to form hydrogen bonding interactions are labelled and highlighted 
(grey sticks). 
 
The predicted poses produced by this docking did not show a clear prediction of 
whether the designed compounds would be likely to bind to Aurora A in a similar 
manner to CD532. The reported docking poses showed big differences even 





designed compounds were still synthesised and tested using the methods 
described (Sections 4.2 and 4.4).  
 Kinase Inhibition Assay 
The ability of the designed compounds based on CD532 and VX-680 to inhibit the 
kinase activity of Aurora A was assessed using the Caliper Mobility-Shift Assay. 
This assay used the mutant Aurora A C290A:C293A, which was prepared in E. coli 
using a construct available in the Bayliss lab. The expressed His-tagged protein 
was purified by IMAC (Immobilised metal ion affinity chromatography) and size 
exclusion chromatography. Successful purification was confirmed by SDS-PAGE 
(Figure 4.9).  
 
Figure 4.9 SDS-PAGE results following final purification of Aurora A C290A:C393A 
mutant. The left lane shows a sample before gel filtration and subsequent 
lanes show eluted fractions. 
 
The Caliper Mobility-Shift Assay uses a fluorescent peptide substrate of the 
enzyme, with the fluorescence intensity eventually used to determine enzyme 
activity. At set time intervals, samples of the enzyme/substrate mixture are taken, 





product are separated by charge using the positive and negative electrodes. The 
detector measures fluorescence over time, with the negatively charged 
phosphorylated product detected first, followed by any unreacted substrate. The 
ratio of the area under the curve (AUC) for these two observed peaks allows the 
determination of the extent of substrate conversion (Figure 4.10). By taking these 
same measurements over time, enzyme kinetics can be studied. In this case, 
synthesised analogues of CD532 and VX-680 were added to the enzyme/substrate 
mixture at a range of concentrations to analyse their ability to inhibit the activity of 
Aurora A. 
 
Figure 4.10 Schematic of the Caliper Mobility-Shift Assay 
 
An enzyme titration (Figure 4.11) and ATP Km determination (Figure 4.12) were 
first performed to identify the optimum concentrations of Aurora A and ATP to use 
to achieve the greatest sensitivity. Concentration used for IC50 experiments were 





concentrations of each of the designed compounds, with the hope that higher 
concentrations of inhibitor would show a decreased substrate turnover. Assays 
were performed in duplicate, and each fluorescence measurement was taken 
twice. Unfortunately, for each of the designed compounds (15a-d), no effect was 
seen on the activity of Aurora A, regardless of the inhibitor concentration (Figure 
4.13).  
 
Figure 4.11 Aurora A kinase titration; a graph of substrate conversion over time for 
various concentrations of Aurora A. Error bars indicate two standard 







Figure 4.12 A graph showing the initial rate of reaction with increasing ATP 




























Figure 4.13 Results of proportion of substrate conversion over increasing concentrations of 15a-c. Error bars indicate two 









Although these results were disappointing, type I inhibition of Aurora, even if 
successful, may not have been the ideal mode of Aurora A inhibition. Existing type 
I inhibitors of Aurora A often suffer from toxicity,81,110 so a different mode of Aurora 
A inhibition which is not competitive with ATP may be useful in overcoming 
selectivity challenges of type I inhibition and toxicity issues arising from the 
inhibition of Aurora A activity in healthy cells.  
 Summary 
The type I mode of inhibition was the branch of the project with the largest amount 
of previous research. Existing compounds in the literature, some of which showed 
a disruptive effect on the Aurora A/N-myc protein-protein interaction, provided a 
starting point for the development of novel inhibitors with improved properties. 
Unfortunately, results from the Caliper mobility shift assay showed the synthesised 
hybrid compounds lost the inhibitory activity on Aurora kinase A. Compounds 
library docking generated a number of small molecules with good Glide scores and 
docking poses which predicted binding at the ATP binding site, although selectivity 
over other kinases and the potential for toxicity would likely be challenges in the 






Chapter 5 Type III Inhibition 
The active conformation of Aurora A contains a salt bridge between Lys162 and 
Glu181 (Figure 5.1). A compound which disrupts this salt bridge interaction could 
lead to development of inhibitors of activation of Aurora A kinase and may affect N-
myc binding, especially if this distortion induces a wider conformational change 
incompatible with N-myc interaction. A compound which disrupts the salt bridge 
interaction while ADP is still able to interact with its binding site would be classified 
as a type III kinase inhibitor. Type III kinase inhibitors may be able to offer greater 
selectivity over other, similar, kinases than existing type I, ATP-competitive 
inhibitors which rely on binding to the highly conserved ATP binding site. To date, 
no type III kinase inhibitors of Aurora A have been described in the literature.  
 
Figure 5.1 The salt bridge formed in the active conformation of Aurora A (yellow 
sticks) from the crystal structure of Aurora A (grey) with N-myc (orange) (PDB 
5G1X) 
 
The inactive conformation of Aurora A, with the salt bridge between Lys162 and 





(Figure 5.2). In order to identify starting points for inhibitor design, this crystal 
structure could be used for virtual screening of compound libraries to identify 
compounds binding in the region between the salt bridge residues. Compounds 






Figure 5.2 Aurora A crystal structure (grey) with the salt bridge residues (yellow 
sticks) and ADP (green sticks) shown. The broken salt bridge is stabilised by 






Analysis of the binding site by SiteMap from the Aurora A/vNAR-D01 crystal 
structure (PDB 5L8L) (retaining the crystallised water molecules) produced 
SiteScores of 1.10 and 1.01 with and without ADP, respectively. Without the water 
molecules, SiteScores were 1.06 and 1.05 with and without ADP. In general, 
scores above 0.8 indicate a “druggable” site.91 Although the score is only a 
prediction of the “druggability” of a target site, the high scores returned is 
reassuring for the potential development of small molecule type III kinase inhibitors 
at this site. 
 Kinase Alignment 
To investigate the question of whether type III kinase inhibitors could offer greater 
selectivity over similar kinases than type I inhibitors, the two proposed binding 
areas were analysed for conservation of amino acids found within each area in the 
most similar kinases to Aurora A. A protein BLAST search was performed using 
the full-length Aurora A sequence to identify the most similar human protein 
sequences for subsequent alignment studies (Table 5.1). The similarity of proteins 
to Aurora A considered the percentage identity, or the proportion of amino acids of 
the same type in the same position as the query protein, as well as the Expectation 
(E) value, which assesses the probability of a similarly scoring sequence being 
found by chance in a database. The total score is calculated using the number of 
matches between sequences and deducting any penalties for mismatches and the 
introduction of gaps. A well-matched protein would show a high total score and 






Table 5.1 Protein BLAST results with highest similarity to Aurora A and a good 
quality crystal structure 
Protein Accession 
Number 
% Identity E value Total 
score 
Aurora A NP_001310234.1 Query 
(100%) 
Query (0) - 
Aurora B NP_001300881.1 71 7e-139 401 
Aurora C NP_001015878.1 68 1e-141 408 
PLK4 BAB69958.1 38 2e-58 207 
PDK1 pdb|3PWY|A 37 9e-49 170 
ULK3 pdb|6FDY|U 35 1e-48 169 
Ribosomal S6 AAH06106.3 39 1e-48 174 
PLK2 pdb|4I5M|A 31 9e-47 165 
 
Before embarking on a more comprehensive analysis, initially the eight kinases 
with highest sequence identity with Aurora A and available good quality crystal 
structures were aligned based on their ATP binding pockets using Maestro 






Figure 5.3 Crystal structure alignment of kinases similar to Aurora A, with Aurora A 
(grey), Aurora B (blue/purple), PLK4 (green), PDK1 (dark pink), Ribosomal S6 
protease (blue), ULK (light pink), PLK2 (yellow) and FLT3 (teal). 
 
Aligning kinases in this way has limited use when working with large numbers of 
kinases. Although it is possible to identify the phosphate end of ADP, little useful 
information about the conservation of different areas of the kinases from this visual 
inspection, even with a limited number of crystal structures included. Furthermore, 
this relied on the availability of good quality crystal structures, which were not 
available for all kinases. However, there is some use to this method, for example 





Comparing only Aurora A and FLT3 kinases, it is possible to see the presence of 
Phe691 of FLT3 in place of the Aurora A residue Leu210 (Figure 5.4). Differences 
like these could present an opportunity to introduce selectivity over related kinases 
by exploiting key differences in structure. Although this direct comparison of two 
structures could be applied multiple times to study all of the related kinases with 
crystal structures, a more “high-throughput” approach, which didn’t rely on the 
availability of good quality crystal structures, was desired. 
 
Figure 5.4 Alignment of Aurora A (grey, PDB 5G1X) and FLT3 (pink, PDB 5XO2) 






For a more quantitative analysis of the degree of conservation between related 
kinases, the amino acid sequences of Aurora A and the 109 most closely related 
kinases (Appendix) were aligned using the multiple sequence alignment programs 
MUSCLE (Multiple Sequence Comparison by Log-Expectation) and ClustalW.111 
The results from both methods were similar throughout the length of the protein, 
and agreed in almost all cases in the specific regions of interest (ATP-binding 
region and salt bridge). The conservation of the DFG loop (a subset is shown in 
Figure 5.5) was also used as a quick check to ensure the alignment was 
reasonable. If this highly conserved motif was not aligned, there may have been an 
error in the selection of sequences or a problem in the alignment. For all 
sequences chosen, the DFG loop was aligned as expected.  
Protein                            
Aurora A N L L L G S - - - - - - A G E L K I A - - - D F G W S 
Aurora B N L L L G L - - - - - - K G E L K I A - - - D F G W S 
Aurora C N L L L G F - - - - - - R G E V K I A - - - D F G W S 
PLK4 N L L L T R - - - - - - N M N I K I A - - - D F G L A 
SNRK N V V F F E - - - - - K Q G L V K L T - - - D F G F S 
MARK3 N L L L D A - - - - - - D M N I K I A - - - D F G F S 
MARK4 N L L L D A - - - - - - E A N I K I A - - - D F G F S 
Greatwall N M L I S N - - - - - - E G H I K L T - - - D F G L S 
PDK1 N I L L N E - - - - - - D M H I Q I T - - - D F G T A 
ULK3 N I L L S - - - - S L E K P H L K L A - - - D F G F A 
Ribo. S6 N I M L S S - - - - - - Q G H I K L T - - - D F G L C 
MARK2 N L L L D A - - - - - - D M N I K I A - - - D F G F S 
PLK2 N F F I N E - - - - - - S M E L K V G - - - D F G L A 
SIK3 N L L L D A - - - - - - N L N I K I A - - - D F G F S 
DCLK2 N L L V C E - - Y P D G T K S L K L G - - - D F G L A 
PLK1 N L F L N E - - - - - - D L E V K I G - - - D F G L A 
DCLK3 N L L V Q R - - N E D K S T T L K L A - - - D F G L A 
CAMK1 N L L Y Y S - - L D E D S K - I M I S - - - D F G L S 
AKT2 N L M L D K - - - - - - D G H I K I T - - - D F G L C 
AKT3 N L M L D K - - - - - - D G H I K I T - - - D F G L C 
SGK1 N I L L D S - - - - - - Q G H I V L T - - - D F G L C 
Figure 5.5 A subset of alignment results using ClustalW, with the DFG loop shown 
to be conserved for all proteins. Amino acids are grouped using the MEGA-X 
colouring (A, F, I, L, M, V in yellow; N, Q, S, T, W in green; D, E in red; K, P, 






All of the amino acids within 10 Å of either ADP or the salt bridge binding site of 
Aurora A were recorded. Using the alignments by MUSCLE and ClustalW, the 
corresponding amino acids for all other kinases were also noted. The percentage 
of proteins containing each amino acid at each position studied were calculated (a 
subset of this data is shown in Table 5.2). 
Table 5.2 A selection of data from kinase alignment analysis showing the 
percentage of each amino acid at some of the positions studied in proximity of 
the salt bridge binding site. Highlighted figures show the percentage of 
proteins with the same amino acid as Aurora A in that position. 
 Res. No. 
(AurA) 
162 163 164 165 166 167 170 172 173 175 176 178 179 180 181 










A 0 3.6 0 1.8 1 7 9.5 6.6 5.8 0.9 13 12 0.9 4.5 0 
C 0 2.7 0 0 0 0 0 0.9 0 0 0.9 3.7 0 4.5 0 
D 0 0 0 21 2 9.3 8.1 10 15 0 5.5 0 1.9 0.9 0 
E 0 7.3 0 5.5 2 8.1 18 7.5 10 10 28 0 10 10 100 
F 0 5.5 1.8 2.7 3 0 0 1.9 0 0.9 0 4.6 10 0 0 
G 0 0 0 0 0 3.5 6.8 0.9 16 1.9 2.8 0 1.9 0 0 
H 0 1.8 0 0.9 1 1.2 0 0.9 2.3 0 4.6 0 1.9 0 0 
I 0 29 42 0 2 1.2 4.1 1.9 0 9.4 0.9 22 14 0 0 
K 100 14 0 18 61 16 19 17 14 4.7 5.5 0 6.5 14 0 
L 0 4.5 26 0 11 10 4.1 3.8 2.3 13 2.8 24 7.4 3.6 0 
M 0 2.7 10 0 1 0 0 1.9 0 0.9 2.8 1.8 7.4 1.8 0 
N 0 0 0 13 0 2.3 2.7 2.8 9.3 0 1.8 0 0 13 0 
P 0 0 0 10 0 8.1 5.4 1.9 2.3 5.7 0.9 0 2.8 0 0 
Q 0 7.3 0 7.3 0 4.7 4.1 4.7 0 0.9 17 0 8.3 7.3 0 
R 0 1.8 0 11 4 9.3 5.4 21 2.3 17 3.7 0 15 24 0 
S 0 0.9 0 7.3 1 9.3 8.1 10 14 6.6 8.3 1.8 0.9 4.5 0 
T 0 1.8 0 0 2 1.2 5.4 3.8 2.3 7.5 0.9 7.3 1.9 6.4 0 
V 0 17 20 0.9 6.1 8.1 0 0 3.5 17 0.9 22 3.7 6.4 0 
W 0 0 0 0 0 0 0 1.9 0 2.8 0 0 1.9 0 0 
Y 0 0 0 0.9 3 0 0 0 0 0 0 0.9 3.7 0 0 
 Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
 
This analysis highlighted a few areas which were very highly conserved among the 





lysine and glutamic acid in all other proteins in this study. This was an unsurprising 
result since this is a key feature across the kinase family. Other positions showed 
more variation. In the set shown above, position 165 of Aurora A is phenylalanine, 
but only 2.7% of the proteins studied also had phenylalanine in this position. Other 
kinases had a range of amino acids in this position, with the most common groups 
being aspartic acid (21%) and lysine (18%). Both of these more common side 
chains at this position are charged at physiological pH and these differences could 
be exploited in later development of inhibitors to acquire selectivity over related 
kinases. 
His176 in Aurora A was another position which gave an interesting result in this 
analysis. Only 4.6% of proteins studied showed histidine in this position, with 
almost all amino acids seen at least once in other kinases. The most frequently 
seen amino acid was glutamic acid (28%). At physiological pH glutamic acid will be 
negatively charged, whereas the basic histidine side chain will be partially 
positively charged. Again, these differences could be exploited to improve 
selectivity at later stages of inhibitor design.  
This information was used to generate a “heatmap” based on conservation of 
amino acids in Aurora A, with the most highly conserved residues shown in red and 
in green the Aurora A amino acids which were seen in the fewest other kinases 
(Figure 5.6). These maps highlighted some highly conserved areas, and some 






Figure 5.6 Amino acid conservation within 10 Å of (A) ADP and (B) the Glu-Lys 
salt bridge. The percentage of proteins studied with the same amino acid as 
Aurora A at each position is shown by different colours. 
 
However, the properties of each amino acid may also play a role. For example, a 
negatively charged acidic side chain such as glutamic acid or aspartic acid could 
both interact with a positively charged component of a small molecule inhibitor. In 
this case, it might be more useful to group amino acids by their properties as 
opposed to treating each amino acid individually. A number of grouping methods 
were considered and the percentages of proteins with each position’s amino acid 
group was calculated (a subset is in Table 5.3). A similar heatmap was generated 
at each target site using this grouping (Figure 5.7) and showed more conservation 
of amino acid type, as expected. The ATP binding site is highly conserved between 
kinases, so a small molecule which relies on this binding may also be able to 
interact with a number of other kinases, making selectivity difficult to achieve. At 
the salt bridge site, there are still a number of highly conserved amino acids, but 
there is greater variation between kinases starting a short distance from the salt 
bridge site. It could be possible to grow a fragment which binds to the salt bridge 
site to a larger, more drug-like molecule which could be capable of exploiting these 





Table 5.3 A selection of kinase alignment analysis showing the percentage of 
proteins with amino acids grouped as shown in proximity of the salt bridge 
binding site. Highlighted figures show the group Aurora A is found in at that 
position. 
 Res. No. 
(AurA) 
162 163 164 165 166 167 170 172 173 175 176 178 179 180 181 










HKR 100 17 0 30 66 27 24 39 19 22 14 0 23 37 0 
DE 0 7.3 0 26 4 17 26 18 26 10 34 0 12 11 100 
AILMFWYV 0 63 100 6.4 27 27 18 18 12 45 20 87 49 16 0 
STNQ 0 10 0 27 3 17 20 22 26 15 28 9.2 11 31 0 
C 0 2.7 0 0 0 0 0 0.9 0 0 0.9 3.7 0 4.5 0 
G 0 0 0 0 0 3.5 6.8 0.9 16 1.9 2.8 0 1.9 0 0 
P 0 0 0 10 0 8.1 5.4 1.9 2.3 5.7 0.9 0 2.8 0 0 
 Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
 
 
Figure 5.7 Conservation of amino acids using the grouping system described. 
Percentages of proteins with amino acids of the same group as Aurora A at 
each position are shown by different colours. 
 
One of the potentially interesting findings from this grouping was Lys143. This 
residue was lysine for only 4.5% of the proteins studied (Aurora A, B and C, 
Myosin light-chain kinase and Mixed lineage kinase 2). When this was combined 
with other basic amino acids providing positively charged side chains at 





acid was even more interesting as it was also identified through virtual screening 
as being able to make hydrogen bonding interactions with multiple fragments 
docked at the salt bridge site (Section 5.2, Figure 5.13).  
 Docking 
Compounds were docked at the salt bridge site using the crystal structure of 
Aurora A in a complex with vNAR-D01, a nanobody used to stabilise the inactive 
conformation (PDB 5L8L). Both fragment and larger compound libraries (around 
152 000 compounds) were docked with and without water to explore the predicted 
impact of any water-mediated interactions and to compare the results from these 
two conditions which are predicted to bind at the site regardless of the presence or 
absence of certain water molecules. At this site, docking was also performed both 
with and without ADP (Error! Reference source not found.). Docking compounds 
with crystallised ADP present would hopefully avoid the identification of ATP-
competitive inhibitors which bind to the hinge region of the ATP-binding site and 
may help to identify compounds which are predicted to bind at the same time as 
ADP. Comparing results (docking poses and Glide scores) for compounds with and 
without ADP could enable the filtering of compounds which are predicted to 







Figure 5.8 The docking conditions used in docking at the salt bridge site, with salt 
bridge residues highlighted (yellow sticks), and ADP (green sticks), vNAR-
D01 (purple) and water (red crosses) shown 
 
For the first round of virtual screening, crystallised ADP was kept in place. When 
fragment libraries were docked most compounds were predicted to bind close to 
the desired target site, near the salt bridge residues Lys162 and Glu181. Some 
poses even predicted hydrogen bonding interactions with the salt bridge side 
chains (Figure 5.9). Binding poses and Glide scores were similar regardless of 
whether crystallised water molecules were included or excluded. When water was 
included, most predicted hydrogen bonding interactions were with Aurora A side 
chains, with only a small number of water-mediated interactions. This lack of 







Figure 5.9 Selected docking poses from fragment libraries with water, showing 
predicted hydrogen bonding interactions with the salt bridge residues Lys162 
and Glu181 (yellow sticks). Other predicted interacting residues are labelled. 
(A) Predicted interaction with Lys161 (compound ID 12P-660, Bionet); (B) 
Predicted interaction with Glu181 (compound ID SEW04444, Maybridge). 
 
A number of fragments were predicted to form interactions to residues within the 
flexible activation loop of Aurora A (Figure 5.10). Under virtual screening 
conditions, the crystallised conformation of the activation loop was not flexible, so 
compounds capable of interacting with these residues could be favoured. However, 
these kinds of interactions may not be seen in vitro, when this loop is flexible. 
When filtering compounds using these results, docking predictions might be more 






Figure 5.10 One example of a fragment docking pose predicting interactions with 
the flexible activation loop (compound ID BAS 00226633, Asinex). Salt bridge 
residues are highlighted (yellow sticks) and interacting residues are labelled. 
 
When larger (non-fragment) compound libraries were docked, similar interactions 
were seen with the activation loop as were seen with fragment docking. Again, the 
removal of crystallised water had little effect on the Glide scores or poses 
generated. As these libraries contained larger compounds, most extended from the 
salt bridge site either towards the activation loop or towards the back of the ATP 






Figure 5.11 One example of drug-like compounds docking with poses extending 
from the salt bridge region (compound ID 9192554, MCCB). Salt bridge 
residues are highlighted (yellow sticks) and interacting residues labelled. 
 
Docking was also performed with ADP removed for two reasons. Primarily, this 
was to investigate whether compounds were predicted to bind more strongly in the 
ATP binding pocket than the target salt bridge site. With ADP in place, compounds 
might have generated docking poses at the target site which might preferentially 
bind to the ATP binding pocket when given the option. To do this, the same 
docking grid coordinates and dimensions were used which covered both areas so 
poses at either site were possible. 
Secondly, these conditions could generate interesting results in their own right. 
Particularly for larger, more drug-like compound libraries to find poses predicted to 
disrupt the salt bridge whilst also able to occupy the ATP binding site. This would 
be more likely to be ATP-competitive, but may still be worth taking forward for in 





As expected, a lot of the highest scoring results gave poses at the ATP binding 
site, for both fragments and larger compounds. The Glide scores were generally in 
the same range as when ADP was included, with a few of the highest results 
reaching scores of -9. Reassuringly, some of the top fragment poses were still 
centred at the salt bridge target site and did not favour the ATP binding hinge 
(Figure 5.12). 
 
Figure 5.12 Docking results with ADP removed showing; (A) predicted pose from 
the Bionet fragment library (ID PS-4737) in the ATP-binding pocket; (B) A 
Maybridge library fragment (ID AC23506) predicted to bind in the salt bridge 
region. Interacting residues are labelled and salt bridge residues are 
highlighted (yellow sticks). 
 
Many of the larger compounds were predicted to bind to the ATP binding site and 
extend to the salt bridge. With water included, a number of water-mediated 
hydrogen bonding interactions were predicted, whereas without water, more direct 










Figure 5.13 Docking results from drug-like compound libraries with ADP removed; 
(A) Some results were predicted to extend towards and even beyond the salt 
bridge region (compound ID ALB-H05615918, MCCB); (B) Many compounds 
were predicted to form hydrogen bonding interaction with water (compound ID 
LMK 22209945, MCCB); (C) With water removed, more interactions to Aurora 
A amino acids were predicted (compound ID ALB-H05231315, MCCB). Salt 
bridge residues are highlighted (yellow sticks) and interacting residues are 
labelled. 
 
If these predictions are accurate there could be a number of fragments able to bind 
at the salt bridge region without interfering with ADP binding. The docking poses 
and Glide scores were used to identify a subset of small molecules to analyse 
further using crystallography and the Caliper mobility shift assay. The first identified 
subset included fragments with the highest Glide scores which satisfied a number 
of prerequisites. First, any fragments with PAINs scaffolds were removed from 
consideration. Fragments also had to show good docking poses when docked with 
ADP in place, with hydrogen bonding interactions predicted with surrounding 
residues without relying on interactions with the flexible activation loop, which may 
not be viable when this loop is free to move. Finally, poses and Glide scores were 
compared between docking with and without ADP present. If a fragment looked 
promising with ADP present, but showed a higher Glide score and a pose which 
overlapped with ADP when removed, this fragment was not added to the final 
subset. Overall, around 130 fragments were taken forward in the first set.  
 Crystallography 
Current published crystal structures of Aurora A in complex with vNAR-D01 have 
all used a mutated form of Aurora A in which the two surface-exposed cysteine 
residues were mutated to alanine (C290A:C393A, PDB 5L8L).  
The formation of Aurora A/vNAR-D01 crystals was attempted using wild-type 





constructs available in the Bayliss lab. Both of the proteins were His-tagged, 
facilitating purification by IMAC, with a final purification by GF (Gel filtration) 
chromatography. SDS-PAGE was used to confirm the purification of each protein 
(Figure 5.14). 
 
Figure 5.14 SDS-PAGE results after final purification; (A) Aurora A following 
purification (expected mass 32.8 kDa); (B) vNAR-D01 following purification 
(expected mass 12.7 kDa) 
The proteins were combined with an excess of vNAR-D01 and the resulting 
complex was isolated by GF (Figure 5.15). The complexes were co-crystallised 







Figure 5.15 SDS-PAGE results of Aurora A/vNAR-D01 complex: the larger Aurora 
A/vNAR-D01 complex can be seen along with an excess of the smaller 
protein, vNAR-D01 
 
Crystallisation conditions were tested using JCSG-plus, PACT premier and 
Classics Lite crystallisation screens.112,113 The chosen screens assess a variety of 
conditions including pH ranging from 4.0 to 10.5, various salts and buffers at a 
range of concentrations and many different precipitants, again at a range of 
concentrations.  
Following incubation of the complexes for a few days at 25 °C to allow crystal 
formation, viable crystals were only observed with ADP co-crystallised under one 






Figure 5.16 Wild-type Aurora A/vNAR-D01 crystal as observed mounted on beam 
I04 (beam size 80.0 x 20.0 m) 
X-ray crystallography, performed at Diamond, of crystals grown under these 
conditions produced data at 1.70 Å. This data was refined in Coot (Crystallographic 
Object-Oriented Toolkit).114 The conformation of the kinase was not altered by the 
addition of the C290A:C393A mutations. Wild-type crystals were also more 
sensitive to damage at lower concentrations of DMSO than the mutated version, 
which is stable even at 20% DMSO. The stability of the crystals at higher DMSO 
concentration means a higher concentration of fragments (stored in DMSO) can be 
soaked into the C290A:C393A crystals. The fact that these mutations do not cause 
changes to the protein conformation meant crystal soaking experiments were 
performed using the more stable, mutated version of Aurora A/vNAR-D01 crystals. 
Based on virtual screening results, an initial set of 130 fragments was selected to 
send for crystal soaking at 5 mM fragment concentration, exposing the crystals to 
5% DMSO. The majority of fragments did not bind to the crystals. Four compounds 
showed binding to other areas of the protein, but did not appear in the salt bridge 





binding mode of this fragment showed similarity to the predicted pose from virtual 
screening (Figure 5.18), giving some confidence in the ability of the virtual 
screening to predict the binding pose of fragments. R-free and B-factor values are 







Figure 5.17 Crystal soaking results from the first set of fragments soaked into 
Aurora A/vNAR-D01 crystals (Compound IDs  (A) SEW03804, (B) AC36409, 








Figure 5.18 A comparison of; (A) the docking pose and (B) crystal soaking binding 
of 22 
 
Following the identification of 22 bound at the target site, this crystal structure was 
used to revisit the binding site analysis. This time, the binding site of interest was 
identified using 22 as the ligand and gave a SiteScore of 1.12. This score is well 
above the “druggable” 0.8 score and is close to the SiteScore of the ATP binding 
site (1.14, see Chapter 4), again giving confidence that this site may be a useful 
target site for small molecules. 
The binding pose of 22 indicated the carboxylic acid group may be important for 
forming interactions with Lys162. Armed with this information, the virtual screening 
results were revisited and fragments which matched all of the previous constraints 
(limited predicted interaction with the activation loop residues, etc.), hadn’t been 
tested in the first set of compounds and contained a carboxylic acid group 
positioned in a similar orientation were chosen. These measures, combined with 
the fact that the most promising, highly scoring compounds had been tested in the 
first round of soaking, meant these compounds often had significantly lower Glide 
scores. This resulted in a set of 85 compounds for the next round of crystal 
soaking. A random selection of other in-house fragments which had not scored 






screening approach was useful, this set should not show any binding to Aurora A. 
In total, 159 fragments were sent for crystal soaking at this point, which had not 
been selected from virtual screening. 
Unfortunately, this second set did not show any compounds binding at the salt 
bridge site. However, five compounds did bind at other areas. Some of these 
fragments bound at sites known to be involved in Aurora A function (e.g. TACC3, 
Figure 5.19A), but some were found at previously uninvestigated sites (Figure 
5.19B). The impact of small molecule interactions at these sites on the activity of 
Aurora A was unknown, so although these fragments did not bind as predicted, 
they were still taken forward for further investigation of their effects on the kinase 






Figure 5.19 Crystal soaking results from the second round of fragments. (A) One 
of the fragments bound near the TACC3 binding site (compound ID LDS-
034188); (B) One of the fragments bound at a previously uninvestigated site 
(compound ID LDS-034251). 
 
A set of 300 compounds from an in-house fragment library chosen with a focus on 
diversity were all sent for crystal soaking. This library had not been used for 
docking studies. These compounds were all stored at a lower concentration of 50 





from crystallography bound at the salt bridge site. Only one fragment bound 
anywhere on Aurora A (Figure 5.20). Although this was disappointing, it did help to 
illustrate the advantages of the virtual screening in identifying useful sets of 
compounds to help narrow down larger libraries. 
 
Figure 5.20 The only fragment found through crystal soaking using the diversity-
focussed in-house fragment library (compound ID Z1270137020) 
 
Based on the one hit bound at the salt bridge site by crystallography, and a hit 
identified through enzyme activity assays run in parallel (Section 5.4), a set of 
analogues were chosen to begin to explore structure activity relationships through 






 Enzyme Activity Assays 
The effect of interesting virtual screening hits and any fragments successfully 
soaked into Aurora A/vNAR-D01 crystals on the kinase activity of Aurora A was 
studied using the Caliper Mobility-Shift Assay, which uses electrophoresis to 
monitor enzyme kinetics. A fluorescent peptide substrate of Aurora A was used. 
Multiple “sips” are taken over time and any phosphorylated product and unreacted 
substrate are separated by charge. Negatively charged phosphorylated product is 
detected first, followed by unreacted substrate, and the ratio of fluorescence 
intensity in these two peaks provides a percentage conversion. Monitoring the 
change in product formation over time can be used to generate enzyme kinetics 
data. Alternatively, reactions can be quenched after a set time and measurements 
taken at a single time point. 
The 127 virtual screening hits identified in the first round of selection (based on 
Glide score, docking pose and the comparison of docking results for the same 
fragment when ADP was included and excluded) were assessed first. Type III 
inhibitors at this site should not compete with ATP binding, so fragments which 
gave better Glide scores without ADP present, or whose binding poses showed an 
overlap with where ADP would bind if it were present, were removed.  
The most interesting virtual screening hits based on these criteria were tested at a 
single concentration (5 mM) where possible for their effect on Aurora A activity. 
The more stable C290A:C393A Aurora A mutant was used in all Caliper tests and 
an enzyme titration was performed to identify the optimal protein concentration for 
greatest sensitivity (Figure 4.11). An ATP Km determination was performed to 
identify the concentration of ATP to use, again for greatest sensitivity (Figure 4.12).  
Following a 30 minute incubation of Aurora A, ATP and fluorescent peptide 
substrate with each of the 127 fragments, the extent of substrate conversion to 
phosphorylated product was measured. Aurora A activity without the addition of a 
fragment was normalised to 100% (Figure 5.21). Plates were set up in duplicate 





In the first set of virtual screening hits tested, most of which were from the in-house 
fragment library, a range of activities was seen (Figure 5.21), usually with small 
error. Virtual screening only provided predictions of a compound’s ability to bind in 
a given area, so it is perhaps unsurprising that only a small proportion of those 

























Figure 5.21 Substrate conversion results with the first set of compounds tested in the Caliper mobility shift assay. 100% 






In the second set of virtual screening hits (Figure 5.22), some of the in-house 
compounds studied had been stored at lower concentrations, so the intended 5 
mM could not be used without increasing the final DMSO concentration to above 
5%. These compounds were tested twice; once with a 5% DMSO concentration, 
which caused the inhibitor concentration to drop below 5 mM, and once at 5 mM, 
which resulted in a DMSO exposure above 5%. In this set, some of the errors were 









































































































Figure 5.22 Substrate conversion results for the second set of compounds (stored at 100 mM) tested in the Caliper 
























































Figure 5.23 Caliper mobility shift assay results for compounds stored below 100 
mM; (Left, blue) Compounds tested at 5 mM and higher DMSO concentration; 
(Right, black) Compounds tested at 5% DMSO and lower than 5 mM. 100% 
conversion was normalised to uninhibited Aurora A control. 
 
Overall, 28 compounds did reduce Aurora A kinase activity to below 50%, giving a 
first “hit-rate” of 22%. This is higher than might be expected from a purely randomly 
selected set of fragments, suggesting the filtering by virtual screening was helpful. 
Interestingly, a few compounds produced Aurora A activity above 100%. Some of 
these had very large error bars, perhaps suggesting a problem in the setup or 
measurement of some samples. However, some did show high Aurora A activity 
without large errors. These results were interesting enough to put forward for 
further investigation, along with all compounds which resulted in Aurora A activity 
under 25% (a hit rate of 6% for all compounds tested in the single point assay). 
IC50 experiments were performed, again using the Caliper Mobility Shift Assay, this 
time with ten 3-fold serial dilutions of each fragment with a top concentration of 5 
mM (when fragments were soluble at 5 mM). The three fragments which showed a 
possible activation of Aurora A activity in the single point assay (39, 42 and 148) 





showed an inhibition of activity in the single point assay, it was not possible to 
generate an IC50 curve. In some cases, some inhibition was seen at the highest 
concentration. However, without testing at even higher concentrations, which was 
not possible due to solubility issues, the curve could not be completed or an IC50 
value determined. 
Three of the fragments investigated did generate data which could be used to find 
an IC50 value (Figure 5.24, Table 5.4). These values were in the millimolar range, 
as might be expected from small fragments. The crystal soaking hit, 22, was also 
tested in this assay and gave an IC50 of 0.6 mM. This fragment had the additional 
benefit of a crystal structure with Aurora A. 
 
Figure 5.24 Graph of proportion of substrate converted to phosphorylated product 






Table 5.4 IC50 values for fragments which gave a full curve 
Compound IC50 Structure 
31 0.4 ± 0.2 mM 
 
57 0.6 ± 0.2 mM 
 
126 0.3 ± 0.2 mM 
 
22 (BTB10042) 0.6 ± 0.1 mM 
 
 
As these experiments only showed inhibition of Aurora A activity, the next step was 
to attempt to determine whether this inhibition was from direct competition with 
ATP, or whether there was a non-competitive or uncompetitive mode of inhibition. 
 ATP Competition 
ATP competition experiments were conducted for the three tested compounds 
which gave clear IC50 curves. The ATP Km was determined for Aurora A with each 
fragment included at the IC50 concentration and at double the IC50 concentration. A 
competitive inhibitor of Aurora A would raise the ATP Km with higher inhibitor 
concentration whilst maintaining the maximum rate of substrate conversion, Vmax. 
This was seen for two of the fragments tested (31 and 126, Figure 5.25-7), with an 







Figure 5.25 Structures of the fragments 31 and 126 
 























31 2 x IC50 Concentration
No inhibitor
 
Figure 5.26 ATP Km determination with 31 at its IC50 concentration, and at 2 × IC50 
concentration 
 























126 2 x IC50 Concentration
No inhibitor
 







Table 5.5 ATP Km results for the compounds analysed for ATP competition 
Compound ATP Km (mM) 
No inhibitor Inhibitor at IC50 
concentration 
Inhibitor at 2 × IC50 
concentration 
31 0.07 ± 0.01 0.15 ± 0.01 0.21 ± 0.02 
57 0.07 ± 0.01 0.05 ± 0.01 0.07 ± 0.01 
126 0.07 ± 0.01 0.28 ± 0.01 0.55 ± 0.05 
 
For the third fragment, the addition of inhibitor did not alter the ATP Km from that 
observed with uninhibited Aurora A (Figure 5.29, Table 5.5). This suggested this 
fragment (57) was a non-competitive inhibitor of Aurora A. The docking pose of this 
fragment showed some similarity to that of 22 (Figure 5.28), and the crystal 
structure of 22 soaked into Aurora A/vNAR-D01 (Figure 5.18). Unfortunately, when 
57 was soaked with these crystals, no crystal structures with the inhibitor bound 
were produced. The docking poses suggest the carboxylic acid groups in each of 
the most promising fragments (22 and 57) might have a key role in their activity. 
The development of some SAR data around these two hits became the next focus. 
 




























57 2 x IC50 Concentration
No inhibitor
 
Figure 5.29 ATP Km determination with 57 at its IC50 concentration, and at 2 × IC50 
concentration 
 Further Investigation of Hit Compounds 
From the two hits identified above, a selection of commercially available analogues 
were chosen (Figure 5.30, Figure 5.31) to explore the potential for further 
development of these fragments. Quick, one- or two-step syntheses were also 
performed to expand this selection where possible.  
 







Figure 5.31 Commercial compounds based on 22 
 
Synthesised compounds included an ester variant of 57, with the hypothesis that 
removing the carboxylic acid, which appeared to be important from the docking 





the carboxylic acid group. Purchased 57 was reacted with methanol in 1,4-dioxane 
with catalytic hydrochloric acid at room temperature overnight (Scheme 2).  
 
Scheme 2: Esterification of 57 
 
This compound was assessed for its effect on Aurora A kinase activity using the 
Caliper mobility shift assay, and did not generate a dose-response curve or IC50 
value. This indicated an importance of the carboxylic acid group, as predicted by 
the docking poses and suggested by the crystal structure of 22. 
The synthesis of a series of analogues of 22 was also planned, using commercially 
available starting materials (Scheme 3), to expand the SAR knowledge 
surrounding the fragment, with the hope of identifying further fragments with the 
potential to begin to grow 22 into a more drug-like compound with increased 
activity. Although these reactions were completed, final products were not fully 
purified before Covid-19-induced lab shutdown. 
 





Commercially available analogues of both 22 and 57 were purchased and 
prepared as 100 mM stock solutions in DMSO. Three of these compounds were 
screened using the Caliper mobility shift assay (Figure 5.32, experiments 
performed by Christopher Arter upon lab re-opening during Covid-19) and IC50 
values determined (Table 5.6).  
























Figure 5.32 Graph of Aurora A activity over increasing concentrations of 22c, 22i 
and 22k 
 
Table 5.6 IC50 values for the tested analogues of 22 
Compound IC50  Structure 
22c 0.9 ± 1 mM 
 
22i 0.4 ± 1 mM 
 







Errors in these values were much higher than had been seen in other experiments, 
partly due to the incomplete IC50 curves generated. It would be useful to repeat 
these experiments with higher fragment concentrations if possible. If these 
compounds do show inhibition of Aurora A kinase, especially in a non-competitive 
manner with respect to ATP, this would be further support of the viability of 22 as a 
starting point for the design of a type III Aurora A inhibitor. 
This section of work was disrupted by Covid-19 and the resulting lab shutdown, so 
the remaining purchased and synthesised compounds were not screened for IC50 
determination or ATP competition investigation, and some synthesis plans could 
not be completed. 
 Summary 
Based on literature findings and the kinase alignment performed here, type III 
inhibition showed promise as an approach to kinase inhibition with the potential to 
introduce selectivity over other kinases and may present opportunities to disrupt 
the Aurora A/N-myc protein-protein interaction. Docking studies helped to narrow 
down the number of compounds taken forward for crystal soaking and in vitro 
assays to a manageable number. The fragment hits identified, one of which was 
shown to be non-competitive with ATP, could be useful starting points for SAR 







Chapter 6 Conclusions and Future Work 
 Conclusions 
The current, variable treatments for neuroblastoma, ranging from observation 
through to aggressive multimodal treatment involving classic, non-specific 
chemotherapy including doxorubicin, cyclophosphamide, and etoposide, among 
others, reflect the variability of this disease, from symptoms, disease progression 
and ultimate long-term outcomes. Unsurprisingly, the most intensive treatment 
pathways in such young patients result in the highest toxicity, with adverse effects 
sometimes persisting way beyond the end of treatment and leading to chronic 
health effects for survivors of this cancer.8, 15,115  
More targeted treatments with fewer toxic effects are required to improve survival, 
particularly for high-risk neuroblastoma, and to minimise long- and short-term side 
effects. Disrupting the Aurora A/N-myc interaction could be a useful approach to 
solving this problem, with neuroblastoma cells shown to become “addicted” to N-
myc stabilisation by Aurora A through this protein-protein interaction.2   
Whilst there is an abundance of possible approaches to identifying compounds 
capable of modulating the activity of Aurora A or disrupting the Aurora A/N-myc 
interaction, one challenge in this project has been to identify the most promising 
methods on which to focus. Computational methods proved helpful in narrowing 
down libraries of compounds to a manageable number of compounds for crystal 
soaking and single point in vitro Caliper mobility shift assays. Further crystal 
soaking of diverse sets of fragments from commercial and in-house libraries helped 
to provide some validation for the in silico screening process as well as highlighting 
other interesting compounds which soaked into sites of interest in this project and 
other Aurora A binding sites which weren’t intended to be the focus of this project.  
Another challenge in this project was to identify which of the possible target sites 
showed the most potential for development of small molecule inhibitors of Aurora 





interaction. A number of factors considered during the course of the project helped 
inform the decision to ultimately focus on the development of type III inhibitors of 
Aurora A, discussed below. 
The initial foray into the design of novel compounds capable of disrupting the 
Aurora A/N-myc interaction involved computational analysis of potential target 
binding sites of Aurora A and in silico screening of commercial and in-house 
libraries. Binding site analysis of the five sites considered highlighted potential 
challenges associated with some approaches. SiteScores below the “druggable” 
level of 0.8 were generated for the type IV and N-myc binding sites considered in 
this project (Table 6.1). The highest SiteScore came from the ATP-binding site, 
which was already known to allow the binding of small molecules, with a number of 
type I inhibitors already reported.45,116,117 The potential for the development of a 
type III inhibitor of Aurora A also showed some promise at this point, with 
SiteScores comfortably above the 0.8 threshold. A further encouraging SiteScore 
was obtained at this site following the soaking of the fragment 22 into Aurora A and 
the subsequent co-crystal structure produced. The SiteScore generated from using 
this fragment to define the binding site for analysis gave more confidence in the 
predicted druggability of this region in developing a type III inhibitor of Aurora A.  
Table 6.1 SiteScores at each of the target sites considered 
Site SiteScore (with water) SiteScore (without 
water) 
N-myc (Trp77) 0.525 0.536 
MES 0.828 0.798 
TPX2 0.708 0.573 
ATP 1.14 1.08 






Compound library docking at each of the target sites highlighted further challenges 
at the N-myc binding site, with very few compounds predicted to bind in the desired 
region and low Glide scores predicting very weak binding to Aurora A. With these 
results, despite the attractiveness of directly blocking the binding of N-myc to 
Aurora A to disrupt the interaction, work on this approach did not progress further. 
The type IV approach to Aurora A inhibition also stalled at this time, with the focus 
shifting to type I and type III inhibition, the two areas with the most encouraging 
computational predictions. 
This decision did not only rely on results from computational modelling. A number 
of type I Aurora A inhibitors had already been reported in the literature,45, 50, 87,110 
with alisertib also in clinical trials.118 Efforts at combining two of these inhibitors 
(Figure 6.1), CD532 and VX-680, in the hope of finding a compound with the ability 
to disrupt the Aurora A/N-myc interaction (as with CD532) whilst avoiding the 
solubility challenges associated with CD532, ultimately failed to produce a hybrid 






Figure 6.1 Hybrid compound design based on published inhibitors CD532 (12) and 
VX-680 (13) 
The type III approach to Aurora A inhibition eventually proved to be one of the most 
promising branches of this project. Alignment of the most closely related human 
proteins to Aurora A from a BLAST search against the Aurora A amino acid 
sequence suggested more conservation of amino acid types around the ATP 
binding site. By contrast, the proposed type III binding site, around the salt bridge 
of Aurora A, showed more variability within the 10 Å radius investigated. Although 
there were still some highly conserved amino acids, particularly those closest to 






variability in amino acid properties. This could indicate the potential to build 
selectivity for Aurora A over other kinases as any fragments are grown into more 
drug-like compounds in the future. 
In silico screening of compound libraries enabled more focussed in vitro screening, 
which resulted in the identification of two fragments, one of which was successfully 
soaked into Aurora A/vNAR-D01 crystals and showed binding which closely 
matched the prediction generated through virtual high-throughput screening. This 
compound also showed activity in the Caliper mobility shift assay with an IC50 of 
0.6 mM.  
Although the second fragment, 57, did not successfully soak into protein crystals, 
an IC50 of 0.6 mM was identified through Caliper and subsequent ATP competition 
experiments indicated the kinase inhibition was non-competitive with respect to 
ATP. Both fragments contained a carboxylic acid group which might interact with 
the positively charged magnesium ions at the ATP binding site.  
The in silico screening results were revisited to focus on fragments containing 
carboxylic acids with docking poses similar to those of 22 and 57. Unfortunately, 
crystal soaking experiments based on this selection of carboxylic acid-containing 
fragments failed to yield any further compounds shown to bind at the desired type 
III binding site. 
Disappointingly, the extent of SAR investigated was restricted by Covid-19. 
Fragments based on the structures of 22 and 57 were purchased or synthesised 
with the intention of determining IC50 values using the Caliper mobility shift assay 
and crystal soaking to assess any binding modes. Three of these fragments were 
tested and IC50 values determined by another PhD student upon lab re-opening, 
the results of which indicated fragments 22c, 22i and 22k might have a similar 
activity to 22, although the large errors in this value means a clear conclusion 







 Future Work 
Previously described ATP-competitive inhibitors have been shown to potently 
inhibit the kinase activity of Aurora A.50 Although the changes made have not been 
successful in improving the potency of this class of inhibitors, there may be useful 
modifications to be made to these structures to improve solubility whilst 
maintaining potency, or increasing the disruptive effect on the Aurora A/N-myc 
interaction. Virtual screening of compound libraries identified some compounds 
and fragments with structures unrelated to any of the previously published Aurora 
A inhibitors. These compounds could be candidates for further in vitro 
investigation, although the reliability of these computational predictions remains to 
be demonstrated for type I inhibitors of Aurora A.  
Although the relatively low potency of the fragments identified in this project 
prevented investigation into their effect on the key protein-protein interaction, future 
work with more potent type III inhibitors of Aurora A would include an analysis of 
their effect on the stability of the Aurora A/N-myc interaction. Other work has used 
fluorescence polarisation to study the effect of an inhibitor on kinase activity or the 
disruption of protein-protein interactions, including the Aurora A/N-myc interaction39 
and may be used to analyse the effect of any promising compounds.119 When 
measuring phosphorylation of a kinase substrate, Immobilised Metal Ion Affinity 
Particle (IMAP) technology allows a metal complex to form with phosphate groups 
on the labelled substrate. A potent kinase inhibitor would prevent phosphorylation 
and formation of this large complex, and a high polarisation value would be 
observed.120 For protein-protein interactions, the effective disruption of the complex 
results in two smaller components, one of which will be fluorescently labelled and 
will give a lower polarisation than the complex.119  
Alternatively, the protein-protein interaction could be analysed using AlphaScreen, 
which uses donor and acceptor beads attached to the two interacting proteins. A 
laser is used to excite the donor bead to induce the formation of singlet oxygen, 
which can travel 200 nm before decaying. If the acceptor bead is within 200 nm of 





wavelength of 615 nm. The donor and acceptor beads are attached to proteins via 
antibodies secured to the beads by streptavidin and biotin.102  
Further SAR investigation around the two key fragments (22 and 57) identified as 
potential type III inhibitors of Aurora A would be a priority in continuing this work. 
With further SAR data from Caliper experiments and crystallography it may be 
possible to begin to grow these fragments into more drug-like molecules, 
potentially increasing potency by targeting key interactions with nearby amino acid 
side chains. This could be achieved using crystal structures with fragments bound 
near the Aurora A salt bridge. By referring to the kinase alignment performed, it 
may be possible to build some selectivity over other kinases by targeting Aurora A 






Chapter 7 Experimental 
 Computational Methods 
7.1.1 Screening Libraries 
The Asinex library99 contains 21872 fragments. The library aims for diversity as 
well as containing groups known to be good synthetic starting points. 
The 2nd Generation Bionet library98 contains 1166 fragments with 445 fragments 
found in currently used pharmaceuticals. The library excludes reactive or 
promiscuous compounds and anything known to aggregate.  
The Enamine -helix mimetic library95 contains around 14000 compounds with 
most obeying Lipinski’s Rule of 5 (molecular weight <500 Da, ≤5 H-bond donors, 
≤10 H-bond acceptors, logD ≤5). The library was designed to contain a diverse 
range of 3D shapes with three groups similar to amino acid side chains projected 
from the core. 
The Enamine fragment library contains 300 fragments under 300 Da with a focus 
on diversity. This library is available in-house. 
The ChemDiv library contains just over 14000 peptidomimetic compounds aimed at 
targeting protein-protein interactions with -helix or -turn mimetics containing 
amino acid side chain-like groups projected.100  
The Chembridge DIVERSet library contains around 100000 compounds selected 
for structure and pharmacophore diversity, filtered for desirable drug-like properties 
(adhering to the Lipinski’s rule of 5).97 
The Maybridge libraries together contain 1000 fragments with a focus on diversity. 
The library complies with the Astex Rule of 3 (molecular weight <300 Da, ≤3 H-
bond donors, H-bond acceptors, ClogP ≤3). The Maybridge compounds are 
available in-house at the University of Leeds. 
The MCCB library contains around 30000 larger compounds from the University of 





All of the libraries were prepared using Ligprep (Schrödinger) with default settings 
(pH 7.0 ± 2.0, specified chirality maintained)121 apart from the number of 
stereoisomers generated, which was reduced from 32 to 2 prior to screening. 
7.1.2 Docking 
All docking was performed using Glide (Schrodinger)122 and either the OPLS2005  
or OPLS3 force fields, with results ranked by docking score. For each screen, 
default Glide SP docking settings were used with the addition of strain correction 
terms. Grid sizes were changed to accommodate each binding site but the 
maximum length of docked compounds was kept at 14 Å. At each site, libraries 
were docked with and without the crystallised water molecules. 
The N-myc site used PDB 5G1X with N-myc removed. The coordinates of N-myc 
residues Met81 and Glu84 were used as centres for the Met81 and Glu84 Glide 
grids, respectively. In the crystal structure the N-myc side chain of Trp77 sits 
between the Aurora A residues Leu189 and Leu193, so these were used to 
generate the Trp77 Glide grid. Grid inner and outer box sizes and centre point 
coordinates (where applicable) for all sites are summarised in Table 7.1. 
At the MES site, PDB 5LXM was used and MES was redocked to give RMSD 
values of 1.21 Å for SP and 1.31 Å for XP (heavy atoms, calculated in place). MES 
was identified as the ligand to generate the Glide grid. The grid size was based on 
docking ligands with a similar size to MES. 
The TPX2 site used PDB 5G1X with N-myc removed and used the Aurora A 
residues His187 and His280 as the centre point for Glide grid generation.   
ADP was redocked at the ATP binding site in each of the chosen crystal structures 
(PDB 5LXM and 5G1X). RMSD values for PDB 5LXM were 2.4505 Å (SP) and 
1.7030 Å (XP). For PDB 5G1X the RMSD values were 0.41 Å (SP) and 0.21 Å 
(XP). Crystallised ADP coordinates were used to make the Glide grid.  
CD532 was redocked into the ATP binding site in the crystal structure of Aurora A 
with CD532 bound (PDB 4J8M). With SP, the RMSD value was 0.53 Å. 





The salt bridge site used the midpoint of Glu162 and Lys181 as the centre for grid 
generation. 
Table 7.1 Dimensions and centre coordinates of Glide grids 








10, 10, 10 24, 24, 24 - 
N-myc Met81 
(PDB 5G1X) 








10, 10, 10 24, 24, 24 - 
MES 10, 10, 10 20.82, 20.82, 
20.82 
- 
TPX2 10, 10, 10 30, 30, 30 - 
ATP (PDB 5G1X) 10, 10, 10 25, 25, 25 44.272, -8.127, 
41.224 




10, 10, 10 24, 24, 24 - 
Salt bridge 10, 10, 10 30, 30, 30 - 
 





Table 7.2 The libraries docked at each site with water. Libraries marked (F) are 
fragment libraries. The Maybridge fragment library was screened using XP at 
the ATP site with PDB 5LXM due to a better RMSD for redocked ADP than 











MES 5LXM  ✓  ✓  ✓  ✓  ✓  
TPX2 5G1X  ✓  ✓  ✓  ✓  ✓  
N-myc 
5G1X  ✓  ✓  ✓  ✓  ✓  
5LXM  − − − − ✓  
ATP 
5G1X  ✓  ✓  ✓  ✓  ✓  
5LXM  − − XP − − 
Salt 
bridge 




✓  ✓  ✓  ✓  ✓  
 











MES 5LXM  ✓  ✓  ✓  ✓  ✓  
TPX2 5G1X  ✓  ✓  ✓  ✓  ✓  
N-myc 5G1X  ✓  ✓  ✓  ✓  ✓  
 5LXM  − − − − − 





 5LXM  − − − − − 
Salt 
bridge 




✓  ✓  ✓  ✓  ✓  
 





Trp77 with water 5G1X ✓  ✓  
Trp77 without water 5G1X ✓  ✓  
Met81 with water 5G1X ✓  ✓  
Met81 without water 5G1X ✓  ✓  
Glu84 with water 5G1X ✓  ✓  
Glu84 without water 5G1X ✓  ✓  
7.1.3 SiteMap 
A prediction of “druggability” for each of the proposed binding sites was acquired 
by SiteMap (Schrödinger).104 Ligands were chosen either from co-crystallised 
compounds (MES and ADP) or a result from virtual screening which sat in the 
intended binding site. Table 9.4 shows the ligand and crystal structure used for 






Table 7.5 Crystal structures and ligands used at each site in SiteMap to generate 
SiteScores 
SITE PDB CODE 
LIGAND USED 



































SPROUT fragment growth analysis used PDB 5LXM with MES defined as the 
ligand and the Aurora A/TPX2 structure as the receptor.  
7.1.5 ROCS 
ROCS version 3.2.1.4123 was used with the Enamine -helix mimetic compound 





three N-myc side chains Trp77, Met81 and Glu84 connected by a carbon chain 
linker to ensure the correct distance between side chain groups. 
7.1.6 Kinase Alignment 
Proteins with highest sequence similarity to Aurora A were found via a BLAST 
(Basic Local Alignment Search Tool) search using the catalytic domain of Aurora A 
(accession NP_001310234.1, residues 1-403) as the search query against all 
human protein entries on the NCBI (National Center for Biotechnology Information) 
database. Results were ranked by sequence similarity and E value and the highest 
ranked 107 discrete protein sequences were collected as FASTA (Fast Adaptive 
Shrinkage-Threshold Algorithm) format. Amino acid sequences were aligned in 
MEGA-X (Molecular Evolutionary Genetics Analysis) using ClustalW and MUSCLE 
(MUltiple Sequence Comparison by Log-Expectation) functions (?).  
Amino acids within the vicinity of the Aurora A salt bridge and ATP binding sites 
were identified through a visual inspection of the surrounding amino acid side 
chains, the identification of side chains within 14 Å of each site and the generation 
of ligand interaction diagrams using Glide (Schrödinger).  
 Protein Expression and Purification 
7.2.1 Physical Methods 
Centrifugation used either a Beckman Avanti J-20XP or J-26XP instrument for 
larger volumes (40 mL and above). Concentration of purified protein used a 
Beckman Allegra X-12R centrifuge. 
Immobilised metal ion affinity chromatography (IMAC) was performed using a 
HisTrap High Performance (HP) column with ÄKTA Prime. His-tagged proteins 
were eluted with HisB buffer (Table 7.6). 
Gel filtration (GF) chromatography was performed using a HiLoad 16/600 






SDS-PAGE was performed using Novex Tris-Glycine precast gels with Novex Tris-
Glycine running buffer at 200 V and 200 mA. Novex SeeBlue Plus2 Pre-Stained 
protein standard was used to assess results.  
7.2.2 General Procedure 
All proteins were expressed in BL21 DE3 RIL E. coli cells grown in LB medium at 
37ºC to OD (optical density) 0.6. BL21 DE3 RIL cells were chloramphenicol 
resistant and protein constructs contained kanamycin resistance genes. Colonies 
were therefore grown in the presence of kanamycin and chloramphenicol. 
Expression was induced by addition of isopropyl b-D-1-thiogalactopyranoside 
(IPTG, 1M, final concentration 0.6 mM). Following centrifugation (3500 rpm, 4ºC, 
15 min) cell pellets were either purified immediately (section 10.2.3-4) or stored at -
80ºC. Buffers specific to this project are described in Table 9.5.  
Table 7.6 Buffer components for protein expression and purification 
Buffer Components 
HisA 50 mM Tris pH 7.5, 0.3 M sodium chloride, 5 mM magnesium 
chloride, 10% glycerol 
HisB 50 mM Tris pH 7.5, 0.3 M sodium chloride, 5 mM magnesium 
chloride, 0.5 M imidazole, 10% glycerol 
Aurora A GF 20 mM Tris pH 7.0, 0.2 M sodium chloride, 5 mM magnesium 
chloride, 5 mM -mercaptoethanol, 10% glycerol 
TEV protease 50 mM Tris pH 7.5, 0.2 M sodium chloride, 5 mM magnesium 
chloride, 5 mM -mercaptoethanol, 10% glycerol  
TES 50 mM Tris pH 8.0, 0.2 mM ethylenediaminetetraacetic acid 
(EDTA), 0.2 M sucrose 
7.2.3 Aurora A 
Purification of both wild-type Aurora A and the mutant C290A:C393A followed the 





were resuspended in HisA buffer with cOmplete, EDTA-free protease inhibitor 
cocktail (Roche). Cells were sonicated (6 cycles of 15 s on, 30 s off at 55% 
amplitude), centrifuged (19000 rpm, 4ºC, 45 min) and filtered (0.45 m pore). 
Filtered lysate was purified by IMAC and presence of the protein was confirmed by 
SDS-PAGE. Relevant fractions were dialysed using SnakeSkin Dialysis Tubing 
(MWCO 3500 Da) with TEV protease buffer and the His-tag cleaved by TEV 
protease (1 mg mL-1, 450 L aliquots). Protein was again purified by IMAC and 
confirmed by SDS-PAGE. Relevant fractions were concentrated (Vivaspin Turbo 
15 (Sartorius) MWCO 5000 Da, 3500 rpm, 4ºC) and any aggregated protein 
removed by GF. Protein presence was confirmed by SDS-PAGE; key fractions 
were concentrated to 103 M (wild-type) and 800 M (C290A:C393A) and stored 
at -80ºC. 
7.2.4 vNAR-D01 
The vNAR-D01 construct contained a non-cleavable C-terminal His-tag for 
purification and expression was targeted to the periplasm. Cell pellets were 
resuspended in TES buffer and centrifuged (10000 g, 4ºC, 30 min). The 
supernatant was filtered and dialysed using SnakeSkin Dialysis Tubing (MWCO 
3500 Da) with HisA buffer. Initial purification was performed by IMAC and presence 
of protein was confirmed by SDS-PAGE. Relevant fractions were concentrated 
(Vivaspin Turbo 15 (Sartorius) MWCO 3000 Da, 3500 rpm, 4ºC). Final purification 
was performed by GF and confirmed by SDS-PAGE. Key fractions were 
concentrated to 43 M and stored at -80ºC. 
 Crystallography 
7.3.1 Wild-Type Aurora A/vNAR-D01 Crystallisation 
Purified vNAR-D01 and wild-type Aurora A proteins were combined with an excess 
of vNAR-D01 and the resulting complex was isolated by GF with Aurora A GF 
buffer. Crystals were obtained with 0.1 M citrate, pH 5.0 with 20% PEG6000 as 





7.3.2 Fragment Soaking 
Fragments stored at a stock concentration of either 50 or 100 mM in DMSO were 
soaked into Aurora A/vNAR-D01 crystals to obtain a final DMSO concentration of 
5% where possible. In some cases, higher DMSO concentrations were used in an 
effort to detect any weak binding fragments by soaking at a higher fragment 
concentration. Most fragment soaking was performed by Mohd Syed Ahanger. 
 Assays 
7.4.1 Caliper 
7.4.1.1 Single Point Assay 
Caliper mobility shift assays were performed using the LabChip EZ Reader. 
Fragments were tested at 5 mM concentration and a maximum DMSO 
concentration of 5% where possible. Reaction mixtures also contained 30 nM 
cysteine-less Aurora A mutant (C290A:C393A), 80 M ATP and 1.5 M fluorescent 
substrate (FL-peptide 21) in Aurora A reaction buffer (50 mM Tris pH 7.5, 200 mM 
NaCl, 5 mM MgCl2, 10% glycerol and 10 mM -mercaptoethanol). Reactions were 
stopped after 30 minutes with the addition of Caliper Separation Buffer (containing 
EDTA) before analysis of substrate phosphorylation using the LabChip EZ Reader. 
Percentage conversion was normalised to uninhibited Aurora A. Each reaction was 
performed at least in duplicate and measurements of conversion for each reaction 
were also taken in duplicate. 
7.4.1.2 IC50 Determination 
For IC50 determination, compound stocks were diluted with 10 3-fold serial dilutions 
in DMSO to obtain a final maximum concentration of 5 mM, with 5% DMSO in the 
final reaction mixture. As above, reaction mixtures also contained 1.5 M 
fluorescent substrate (FL-peptide 21), 80 M ATP and 50 nM Aurora A 
(C290A:C393A) in Aurora A reaction buffer. In some cases, compounds were 
insoluble at the highest concentrations, in which case this top concentration was 





Controls included one sample containing all reaction mixture components without 
any inhibitor, and one sample containing all reaction mixture components save 
Aurora A kinase. Each reaction was again performed at least in duplicate. 
Substrate conversion was monitored using the LabChip EZ Reader with 40 cycles 
of measurements taken over ca. 40 minutes. Blockages in some channels 
occasionally caused the delay of fluorescence detection and the misidentification of 
fluorescence peaks by the automated system. This necessitated the manual 
adjustment of this identification to generate useful data.  
7.4.1.3 ATP Km 
ATP Km experiments were performed using 12 3-fold serial dilutions of ATP with a 
maximum assay concentration of 3 mM. Reaction mixtures also contained 50 nM 
Aurora A (C290A:C393A), 1.5 M fluorescent substrate (FL-peptide 21) and 
inhibitor at either the IC50, half the IC50 or double the IC50 concentration, where 
inhibitor was included, in Aurora A reaction buffer.  
Substrate conversion was monitored in the same way as for IC50 determination 
(see 7.4.1.2). The initial, linear portion of the reaction was used to determine ATP 
Km using Michaelis Menten kinetics in GraphPad Prism versions 5.0-9.0.124 
 Synthesis 
Some synthesis and analysis was affected by Covid-19 and the resulting lab 
shutdown. 
7.5.1 Materials 
All purchased chemicals and solvents were used without further purification unless 
otherwise stated. 
7.5.2 Physical Methods 
1H Nuclear Magnetic Resonance spectra were recorded at 298 K on either a 
Bruker AV 500 or a Bruker AV-NEO spectrometer at 500 MHz (1H) and 125 MHz 
(13C), or a Bruker AV3HD-400 instrument at 400 MHz (1H) and 100 MHz (13C). 





3.0 or 4.0 (Bruker). Coupling constants (J) are reported to the nearest 0.1 Hz for 1H 
and to the nearest 1 Hz for 13C, with 1H chemical shift reported to the nearest 0.01 
ppm and 13C chemical shift to the nearest 0.1 ppm. NMR splitting assigned as: 
singlet (s), doublet (d), triplet (t), apparent (app), multiplet (m).  
LCMS was performed on a Thermo Scientific Dionex UltiMate with a gradient of 
MeCN (5-95%) in water, each containing 0.1% formic acid, with a flow rate of 1 mL 
min-1 on a C18 reverse phase column. Compounds detection used a diode array 
detector and a Bruker amaZon speed mass spectrum analyser.  
Infrared spectroscopy was performed using a Bruker Alpha Platinum ATR FTIR 
instrument. Biotage silica column chromatography used an Isolera Four EXP with 
Spektra. 
7.5.3 Type I Inhibitors 
General Procedure 1 
Sodium hydride (60% dispersion in mineral oil) was added to a solution of the 
relevant 4-nitrophenyl compound in anhydrous tetrahydrofuran (0.1-0.2 M) at 0 ºC 
and stirred for 30 min. This mixture was then added to a solution of 17 in 
tetrahydrofuran and stirred at 0 ºC. The reaction mixture was diluted with ethyl 
acetate, washed with saturated sodium bicarbonate and extracted with ethyl 
acetate (3 × 100 mL). The combined organic layers were dried over sodium sulfate, 
filtered and the solvent removed under reduced pressure. The resulting crude 
material was purified by recrystallisation from methanol. 
General Procedure 2 
3-Amino-5-methylpyrazole was stirred with diisopropylethylamine in anhydrous 
dimethylformamide at 85 ºC for 10 min. Compound 18 was added and the reaction 
stirred at room temperature. The mixture was diluted with ethyl acetate, washed 
with sodium bicarbonate and extracted with ethyl acetate. The combined organic 
layers were dried over sodium sulfate, filtered and the solvent removed under 
reduced pressure. The intermediate product was dissolved in 1-methylpiperazine 





with saturated sodium bicarbonate, and extracted with ethyl acetate (3 × 50 mL). 
The combined organic layers were dried over sodium sulfate, filtered and the 
solvent removed under reduced pressure. 
General Procedure 3 
Di-tert-butyl-dicarbonate was added to a solution of 19 in methanol with 
triethylamine and stirred at room temperature. Dichloromethane and saturated 
sodium bicarbonate were added to the reaction mixture before extracting with 
dichloromethane (3 × 50 mL). The combined organic layers were dried over 
sodium sulfate, filtered and the solvent removed under reduced pressure. 
4,6-dichloro-2-(methylsulfonyl)pyrimidine (17) 
 
4,6-Dichloro-2-(methylthio)pyrimidine (546 mg, 2.80 mmol) was dissolved in 
dichloromethane (10 mL) at 0 ºC with addition of m-chloroperoxybenzoic acid (1.82 
g, 10.5 mmol) over 20 min and stirred at room temperature for 12 h. The reaction 
was diluted with ethyl acetate (20 mL), washed with a mixture of aqueous sodium 
thiosulfate/sodium bicarbonate (2:1, 30 mL) and extracted with ethyl acetate (3 × 
30 mL). The combined organic layers were dried over sodium sulfate, filtered and 
the solvent removed under reduced pressure to give the crude product, a pale 
yellow solid, which was purified using flash column chromatography on silica gel 
(50-70% ethyl acetate/petroleum ether) to produce the title compound (17) as a 
colourless powder (496 mg, 2.18 mmol, 78%). 1H NMR H/ppm (400 MHz, DMSO-
d6) 8.44 (1H, s, 3-H), 3.45 (3H, s, methyl C-H3); 13C NMR C/ppm (100 MHz, 
DMSO-d6) 165.3 (C2), 163.1 (C1), 125.8 (C3), 39.7 (SO2Me)  
This compound was synthesised via an unmodified literature procedure.109 All 







Following General Procedure 1, sodium hydride (120 mg, 5.20 mmol) was added 
to a solution of 4-nitrophenol (412 mg, 2.96 mmol, 0.20 M) in anhydrous 
tetrahydrofuran (15 mL) at 0 ºC and stirred for 30 min. This mixture was then 
added to a solution of 17 (480 mg, 2.11 mmol, 0.14 M) in tetrahydrofuran (15 mL) 
at 0 ºC and stirred for 4 h. The reaction mixture was diluted with ethyl acetate (30 
mL), washed with saturated sodium bicarbonate (50 mL) and extracted with ethyl 
acetate (3 × 100 mL). The combined organic layers were dried over sodium sulfate, 
filtered and the solvent removed under reduced pressure. The resulting crude 
material was purified by recrystallisation from methanol to yield the title compound 
as colourless crystals (129 mg, 0.45 mmol, 21%). 1H NMR H/ppm (400 MHz, 
DMSO-d6) 8.37 (2H, d, J = 7.2 Hz, 6-H), 7.88 (1H, s, 3-H), 7.62 (2H, d, J = 6.8 Hz, 
5-H); 13C NMR C/ppm (100 MHz, DMSO) 162.8 (C1), 162.7 (C2), 156.7 (C4), 
145.2 (C7), 125.8 (C6), 122.8 (C5), 117.2 (C3) 
This compound was synthesised via an unmodified literature procedure.109 All 
analytical data agreed with the literature data. 
4, 6-dichloro-2-(4-nitrothiophenoxy)pyrimidine (18b) 
 
Following General Procedure 1, sodium hydride (150 mg, 6.60 mmol) was added 
to a solution of 4-nitrothiophenol (430 mg, 2.77 mmol, 0.18 M) in anhydrous 
tetrahydrofuran (15 mL). This was added to a solution of 17 (459 mg, 2.42 mmol, 





diluted with ethyl acetate (30 mL), washed with saturated sodium bicarbonate (50 
mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layers 
were dried over sodium sulfate, filtered and the solvent removed under reduced 
pressure. The crude material was taken forward to the next step of the reaction. 
LCMS m/z [M]- found 299.99, requires 299.95 
4, 6-dichloro-2-(4-nitroaniline)pyrimidine (18c) 
 
4-Nitroaniline (175 mg, 1.27 mmol) was dissolved under nitrogen in anhydrous 
tetrahydrofuran (10 mL) and cooled to -70 ºC. Sodium bis(trimethylsilyl)amide (1 M 
solution in tetrahydrofuran, 1.8 mL, 1.80 mmol) was added, followed by a solution 
of 17 (205 mg, 0.90 mmol, 0.09 M) in anhydrous tetrahydrofuran (10 mL). The 
resulting mixture was stirred for 16 h, followed by the addition of glacial acetic acid 
(10 mL). The crude product was extracted with brine (20 mL) and a mixture of ethyl 
acetate/hexane (1:1, 30 mL). The organic layers were dried over sodium sulfate, 
filtered and the solvent removed under reduced pressure. The crude material was 









3-Amino-5-methylpyrazole (83 mg, 0.85 mmol) was stirred with 
diisopropylethylamine (0.1 mL, 0.5 mmol) in anhydrous dimethylformamide (5 mL) 
at 85 ºC for 10 min. Compound 18a (104 mg, 0.36 mmol) was added and the 
reaction stirred at room temperature for 16 h. The mixture was diluted with ethyl 
acetate (10 mL), washed with saturated sodium bicarbonate (20 mL) and extracted 
with ethyl acetate (3 × 50 mL). The combined organic layers were dried over 
sodium sulfate, filtered and the solvent removed under reduced pressure. The 
intermediate product was dissolved in 1-methylpiperazine (5 mL) and stirred at 110 
ºC for 30 min. The reaction mixture was diluted with ethyl acetate (20 mL), washed 
with saturated sodium bicarbonate (30 mL) and extracted with ethyl acetate (3 × 50 
mL). The combined organic layers were dried over sodium sulfate, filtered and the 
solvent removed under reduced pressure. The crude material was purified by flash 
column chromatography on silica gel (0-20% methanol/dichloromethane) to 
produce the title compound (19a) as a pale yellow solid (125 mg, 0.30 mmol, 44%). 
1H NMR H/ppm (400 MHz, DMSO-d6) 11.84 (1H, s, NH), 9.34 (1H, s, pyrazole 
NH), 8.30 (2H, d, J = 9.0 Hz, 7-H), 7.43 (2H, d, J = 9.0 Hz, 6-H), 6.36 (1H, s, 3-H), 
5.64 (1H, s, 13-H), 3.44 (s, 9-H2), 2.39 (4H, s, 10-H2) 2.23 (3H, s, 15-H3), 2.07 (3H, 
s, 11-H3); HRMS m/z (M+H)+ found 411.1884, requires 411.1888 
This compound was synthesised via an unmodified literature procedure.109 All 








3-Amino-5-methylpyrazole (100 mg, 1.03 mmol) was stirred with 
diisopropylethylamine (0.25 mL, 1.25 mmol). Compound 18b (273 mg, 0.90 mmol) 
was added and the reaction stirred at 85 ºC for 48 h. The intermediate product was 
dissolved in 1-methylpiperazine (5 mL) and stirred at 110 ºC for 30 min. The crude 
material was taken forward to the next step of the reaction. LCMS m/z [M]- found 




3-Amino-5-methylpyrazole (37 mg, 0.35 mmol) was stirred with 
diisopropylethylamine (0.6 mL, 0.35 mmol). Compound 18c (84 mg, 0.29 mmol) 
was added and the reaction stirred at 85 ºC for 48 h. The intermediate product was 
dissolved in 1-methylpiperazine (5 ml) and stirred at 110 ºC for 16 h. The crude 
material was taken forward to the next step of the reaction. LCMS m/z [M+H]+ 








Di-tert-butyl-dicarbonate (206 mg, 0.94 mmol) was added to a solution of 3 (81 mg, 
0.20 mmol, 0.02 M) in methanol (10 mL) with triethylamine (0.15 mL, 1.1 mmol) 
and stirred at room temperature overnight. Dichloromethane (20 mL) and saturated 
sodium bicarbonate (50 mL) were added to the reaction mixture before extracting 
with dichloromethane (3 × 50 mL). The combined organic layers were dried over 
sodium sulfate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash column chromatography on silica gel (0-20% 
methanol/dichloromethane) to produce the title compound (20a) as a yellow oil (16 
mg, 0.03 mmol, 16%). 1H NMR H/ppm (400 MHz, DMSO-d6) 8.19 (2H, d, J = 9.1 
Hz, 7-H), 7.49 (1H, s, NH), 7.26 (2H, d, J = 9.1 Hz, 6-H), 6.53 (1H, s, 3-H) 5.82 
(1H, s, 13-H), 3.53 (4H, t, J = 4.8 Hz, 9-H2), 2.36 (4H, t, J = 4.8 Hz, 10-H2), 2.34 
(3H, s, 15-H3), 2.24 (3H, s, 11-H3), 1.54 (9H, s, boc CH3); 13C NMR C/ppm (100 
MHz, DMSO-d6) 164.9 (C2), 163.5 (C4), 160.5 (C1), 158.6 (C5), 150.3 (C12), 
148.6 (C16), 144.5 (C8), 144.3 (C14), 125.1 (C7), 122.5 (C6), 102.2 (C13), 84.4 
(C3), 81.7 (C17), 54.6 (C10), 45.2 (C11), 44.1 (C9), 28.0 (C18), 14.5 (C15) 
This compound was synthesised via an unmodified literature procedure.109 All 








To a solution of 19b (270 mg, 0.63 mmol, 0.06 M) in 1,4-dioxane (10 mL) were 
added triethylamine (0.4 mL, 2.8 mmol), di-tert-butyl-dicarbonate (610 mg, 2.8 
mmol) and 4-dimethylaminopyridine (8 mg, 0.07 mmol). The reaction mixture was 
heated at reflux temperature for 16 h. Dichloromethane (20 mL) was added to the 
cooled mixture, which was washed with saturated sodium bicarbonate (50 mL) and 
extracted with dichloromethane (3 × 50 mL). The organic layers were dried over 
sodium sulfate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash column chromatography on silica gel (0-5% 
methanol/dichloromethane) to produce the title compound (20b) as a yellow oil 
(215 mg, 0.41 mmol, 65%). This compound was taken forward without full 
purification. LCMS m/z [M]- found 525.20, requires 525.21 
This compound was synthesised via a literature procedure.109 Analytical data 








To a solution of 19c (156 mg, 0.38 mmol, 0.04 M) in 1,4-dioxane (10 mL) were 
added triethylamine (0.4 mL, 2.8 mmol), di-tert-butyl-dicarbonate (610 mg, 2.8 
mmol) and 4-dimethylaminopyridine (8 mg, 0.07 mmol). The reaction mixture was 
heated at reflux temperature for 16 h. Dichloromethane (20 mL) was added to the 
cooled mixture, which was washed with saturated sodium bicarbonate (50 mL) and 
extracted with dichloromethane (3 × 50 mL). The organic layers were dried over 
sodium sulfate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash column chromatography on silica gel (0-5% 
methanol/dichloromethane) to produce the title compound (20c) as a yellow oil (42 
mg, 0.08 mmol, 21%). This compound was taken forward without full purification. 








Ammonium formate (16 mg, 0.2 mmol) and 20a (33 mg, 0.06 mmol) were 
dissolved in ethanol (5 mL) and treated with 10% palladium on carbon (80 mg, 0.03 
mmol). The reaction mixture was stirred at reflux temperature for 2 h. The resulting 
mixture was filtered over Celite and the solvent removed under reduced pressure. 
The crude material was dissolved in dichloromethane (10 mL) and washed with 
saturated sodium bicarbonate (20 mL) and water (20 mL). The organic layers were 
dried over sodium sulfate, filtered and the solvent removed under reduced 
pressure to give the title compound (21b) as a dark yellow solid (26 mg, 0.05 
mmol, 83%) which was taken forward without full purification. LCMS m/z [M]- found 








Ammonium formate (150 mg, 2.3 mmol) and 20b (203 mg, 0.38 mmol) were 
dissolved in ethanol (10 mL) and treated with 10% palladium on carbon (100 mg, 
0.04 mmol). The reaction mixture was stirred at reflux temperature for 2 h. The 
resulting mixture was filtered over Celite and the solvent removed under reduced 
pressure. The crude material was dissolved in dichloromethane (10 mL) and 
washed with saturated sodium bicarbonate (30 mL) and water (30 mL). The 
organic layers were dried over sodium sulfate, filtered and the solvent removed 
under reduced pressure to give the title compound (21b) as a dark yellow solid 
(148 mg, 0.30 mmol, 79%) which was taken forward without full purification. LCMS 




Ammonium formate (38 mg, 0.60 mmol) and 20c (35 mg, 0.07 mmol) were 
dissolved in ethanol (10 mL) and treated with 10% palladium on carbon (30 mg, 
0.01 mmol). The reaction mixture was stirred at reflux temperature for 2 h. The 
resulting mixture was filtered over Celite and the solvent removed under reduced 
pressure. The crude material was dissolved in dichloromethane (10 mL) and 
washed with saturated sodium bicarbonate (30 mL) and water (30 mL). The 
organic layers were dried over sodium sulfate, filtered and the solvent removed 
under reduced pressure to give the crude compound, which was taken forward 









21a (22 mg, 0.04 mmol) and 3-trifluoromethylphenyl isocyanate (0.10 mL, 0.5 
mmol) were stirred in dichloromethane (6 mL) at room temperature for 20 h. The 
resulting mixture was washed with saturated sodium bicarbonate (25 mL) and 
extracted with dichloromethane (3 × 25 mL). The organic layers were dried over 
sodium sulfate, filtered and the solvent removed under reduced pressure. The 
crude material was purified by flash column chromatography (0-5% 
methanol/dichloromethane) to produce the Boc-protected version of the title 
compound (15a) as a yellow oil. This intermediate (11 mg, 0.036 mmol) was 
dissolved in dichloromethane (2 mL), to which was added hydrochloric acid (2M in 
diethyl ether, 2 mL) and the mixture stirred at room temperature for 2 h. The 
solvent was removed under reduced pressure and the crude material was purified 
by flash column chromatography on silica gel (0-5% methanol/dichloromethane) to 
produce the title compound (15a) as the hydrochloride salt, a colourless solid (7 
mg, 0.01 mmol, 31%). 1H NMR H/ppm (400 MHz, CD3OD) 8.12 (1H, s, NH), 7.92 
(1H, s, 21-H), 7.64-7.71 (3H, m, 18-H, 19-H, 20-H), 7.08-7.19 (4H, m, 6-H, 7-H), 
6.81 (1H, s, 13-H), 6.56 (1H, s, 3-H), 3.32-3.50 (8H, m, 9-H, 10-H), 2.31 (3H, s, 15-
H), 2.21 (3H, s, 11-H); LCMS m/z (M+H)+ found 568.59, requires 568.58 
This compound was synthesised via a literature procedure.109 Analytical data 









21b (33 mg, 0.066 mmol) and m-tolyl isocyanate (0.15 mL, 2.1 mmol) were stirred 
in dichloromethane (10 mL) at room temperature for 24 h. The resulting mixture 
was washed with saturated sodium bicarbonate (25 mL) and extracted with 
dichloromethane (3 × 25 mL). The organic layers were dried over sodium sulfate, 
filtered and the solvent removed under reduced pressure. The crude material was 
purified by flash column chromatography on silica gel (0-5% 
methanol/dichloromethane) to produce the Boc-protected version of the title 
compound (15b) as a yellow oil. This intermediate (23 mg, 0.036 mmol) was 
dissolved in dichloromethane (2 mL), to which was added hydrochloric acid (2M in 
diethyl ether, 2 mL) and the mixture stirred at room temperature for 2 h. The 
solvent was removed under reduced pressure and the crude material was purified 
by flash column chromatography (0-5% methanol/dichloromethane) to produce the 
title compound (15b) as the hydrochloride salt, a yellow solid (10 mg, 0.018 mmol, 
33%). 1H NMR H/ppm (400 MHz, CDCl3) 8.03-8.18 (1H, m, 21-H), 7.43-7.84 (3H, 
m, 18-H, 19-H, 20-H), 7.08 (1H, s, NH), 6.90-7.08 (4H, m, 6-H, 7-H), 6.77 (1H, s, 
13-H), 6.35 (1H, s, 3-H), 2.60-2.90 (11H, m, 9-H, 10-H, 11-H), 2.28 (3H, s, 15-H); 
LCMS m/z [M+H]+ found 530.24, requires 529.23 
This compound was synthesised via a literature procedure.109 Analytical data 









Compound 21b (29 mg, 0.058 mmol) and 3-methoxy phenyl isocyanate (0.10 mL, 
1.1 mmol) were stirred in dichloromethane (10 mL) at room temperature for 18 h. 
The resulting precipitate was filtered and washed with diethyl ether (10 mL). The 
crude material was purified by flash column chromatography on silica gel (0-5% 
methanol/dichloromethane) to produce the Boc-protected version of the title 
compound as a yellow oil. This intermediate (17 mg, 0.026 mmol) was dissolved in 
dichloromethane (2 mL), to which was added hydrochloric acid (2M in diethyl ether, 
2 mL) and the mixture stirred at room temperature for 2 h. The solvent was 
removed under reduced pressure and the crude material was purified by flash 
column chromatography on silica gel (0-5% methanol/dichloromethane) to produce 
the title compound (15c) as the hydrochloride salt, a yellow solid (8 mg, 0.013 
mmol, 36%). 1H NMR H/ppm (400 MHz, CDCl3) 8.03-8.08 (1H, m, 21-H), 7.58-
7.72 (3H, m, 18-H, 19-H, 20-H), 7.25 (1H, s, NH), 6.80-6.94 (4H, m, 6-H, 7-H), 6.73 
(1H, s, 13-H), 6.56 (1H, s, 3-H), 3.37-3.73 (8H, m, 9-H, 10-H), 2.35 (3H, s, 15-H), 
2.25 (3H, s, 11-H); LCMS m/z [M+H]+ found 546.24, requires 546.23 
This compound was synthesised via a literature procedure.109 Analytical data 








7.5.4 Type III Inhibitors 
Methyl 9H-xanthene-9-carboxylate (149) 
 
Xanthene-9-carboxylic acid (162 mg, 0.72 mmol) was dissolved in 1,4-dioxane (20 
mL), followed by the addition of methanol (0.1 mL, 2.5 mmol) and sulfuric acid (0.1 
mL). The reaction mixture was stirred at reflux for 24 h. The reaction mixture was 
poured into ice water (100 mL) before extracting with diethyl ether (3 × 50 mL) and 
washing with water (2 × 50 mL), ice-cold saturated sodium bicarbonate (3 × 20 mL) 
and saturated sodium chloride (1 × 50 mL). The combined organic layers were 
dried over sodium sulfate, filtered and the solvent removed under reduced 
pressure to yield the title compound as an off-white solid (115 mg, 0.48 mmol, 
67%). 1H NMR H/ppm (400 MHz, CD3OD) 7.30-7.36 (4H, m, 2, 5, 7, 10-H), 7.09-
7.14 (4H, m, 3, 4, 8, 9-H), 5.10 (1H, s, 11-H), 3.64 (3H, s, 13-H)  
All analytical data agreed with the literature data.125 
Ethyl 1-oxo-1, 2, 3, 4-tetra-hydronaphthalene-2-carboxylate (151) 
 
-Tetralone (0.18 mL, 1.3 mmol), diethyl carbonate (2 mL, 1.6 mmol), sodium 
hydride (60% dispersion in oil, 110 mg) and anhydrous methanol (0.1 mL) were 
stirred together under nitrogen at 80 ºC for 2 h. The mixture was cooled before 
adding hydrochloric acid (5 mL, 1 M) and then extracted with ethyl acetate (3 × 30 
mL). The organic layers were dried over sodium sulfate and the solvent removed 
under reduced pressure to produce a yellow oil (320 mg), which was carried 
forward without further purification. 






A solution of 151 (58 mg) in tetrahydrofuran (5 mL) was combined with a solution 
of lithium hydroxide (62 mg, 2.6 mmol, 0.52 M) in water (5 mL) at 4 ºC. 
Hydrochloric acid (3 mL, 1 M) was added and the mixture stirred for 1 h to form a 
yellow precipitate. 
Ethyl 2-oxo-1, 2, 3, 4-tetrahydronaphthalene-1-carboxylate (154) 
  
-Tetralone (0.18 mL, 1.3 mmol) diethyl carbonate (2 mL, 1.6 mmol), sodium 
hydride (60% dispersion in oil, 113 mg) and anhydrous methanol (0.1 mL) were 
stirred together under nitrogen at 80 ºC for 2.5 h. The mixture was cooled before 
adding hydrochloric acid (5 mL, 1 M) and then extracted with ethyl acetate (3 × 30 
mL). The organic layers were dried over sodium sulfate and the solvent removed 
under reduced pressure to produce a yellow oil (255 mg) which was carried 
forward without further purification. 
2-oxo-1, 2, 3, 4-tetrahydronaphthalene-1-carboxylic acid (155) 
 
A solution of 154 (51 mg) in tetrahydrofuran (5 mL) was combined with a solution 
of lithium hydroxide (53 mg, 2.2 mmol, 0.44 M) in water (5 mL) at 4 ºC. 
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Appendix 2: Aurora A protein BLAST results 
Table 9.1 Protein BLAST results with similarity to Aurora A 
Protein Accession 
Number 
% Identity E value Total 
score 
Aurora A NP_001310234.1 Query 
(100%) 
Query (0) - 
Aurora B NP_001300881.1 71 7e-139 401 
Aurora C NP_001015878.1 68 1e-141 408 
PLK4 BAB69958.1 38 2e-58 207 
SNRK AAH71567.1 36 3e-49 181 
MARK3 pdb|2QNJ|A 35 3e-49 172 
MARK4 pdb|5ES1|A 34 4e-49 172 
Greatwall 
kinase 
pdb|5LOH|A 35 4e-49 172 
PDK1 pdb|3PWY|A 37 9e-49 170 
ULK3 pdb|6FDY|U 35 1e-48 169 
Ribosomal S6 AAH06106.3 39 1e-48 174 
MARK2 pdb|5EAK|A 33 6e-47 166 
PLK2 pdb|4I5M|A 31 9e-47 165 
SIK3 XP_016872913.1 34 8e-47 175 
DCLK2 XP_016863321.1 35 2e-46 172 
PLK1 pdb|3THB|A 33 1e-44 160 
DCLK3 NP_208382.1 35 1e-44 166 





AKT2 pdb|1MRV|A 36 2e-43 157 
AKT3 NP_001193658 33 4e-43 159 
SGK1 pdb|3HDM|A 36 5e-43 157 
SIK1 NP_775490.2 31 3e-42 160 
SGK2 AAV38901.1 35 7e-41 151 
BRSK1 NP_115806.1 30 2e-40 155 
SNF1-like 
kinase 
EAX09496.1 31 3e-40 155 
CAMK4 pdb|2W4O|A 33 4e-40 148 
DAPK3 pdb|1YRP|A 34 8e-40 145 
ROCK1 pdb|3TV7|A 33 2e-38 145 
SAD-A AAS86443.1 30 4e-38 149 
CAMK2 pdb|6CMJ|A 32 1e-37 141 
DAPK1 pdb|1ZWS|A 32 1e-37 140 
DAPK2 pdb|1Z9X|A 32 2e-37 140 
MST4 AAH99843.1 32 7e-37 141 
ROCK2 pdb|4L6Q|A 31 5e-36 139 
Chk2 pdb|2CN5|A 33 5e-36 137 
CDK3 NP_001249.1 30 9e-36 135 
PKC BAU98542.1 32 7e-36 142 
PKC NP_997700.1 32 1e-35 141 
BRSK2 NP_001243559.1 30 1e-35 142 





PKN2 AAI25200.1 33 5e-35 140 
ULK2 pdb|6QAT|A 36 5e-35 133 
MAST3 NP_055831.1 29 6e-35 140 
PKC NP_001341605.1 31 6e-35 139 
MRCK NP_006026.3 35 8e-35 140 
MRCK AAI36334.1 33 8e-35 140 
ULK1 pdb|4WNO|A 33 1e-34 132 
MKNK1 pdb|2HW6|A 31 1e-34 132 
MAST2 AAH06166.1 30 3e-34 137 
CDK5 pdb|4AU8|A 30 7e-34 130 
CDK2 pdb|5K4J|A 30 7e-34 130 
Nek3 NP_002489.1 30 2e-33 133 
Nek2 pdb|2W5A|A 32 5e-33 127 
PKC pdb|5LIH|A 28 7e-33 129 
MLCK BAB21504.1 26 7e-33 134 
SLK3 AAB82560.1 31 9e-33 130 
PKC AAA36488.1 28 3e-32 131 
CDK1 pdb|4Y72|A 29 3e-32 126 
PKN1 AAH40061.1 33 4e-32 131 
PAK6 pdb|4KS7|A 30 7e-32 125 
PKD1 ABE96833.1 32 8e-32 130 
PKC CAA53384.1 32 8e-32 130 





DMPK AAC14450.1 34 2e-31 128 
MYLK2 NP_149109.1 30 3e-31 128 
MAPKAPK3 NP_001230854.1 31 3e-31 125 
Nek1 pdb|4APC|A 27 3e-31 124 
PAK2 NP_002568.2 27 4e-31 127 
STK4 pdb|3COM|A 29 4e-31 123 
PSKH2 NP_149117.1 28 5e-31 124 
Chk1 pdb|4FSY|A 29 7e-31 122 
Nek7 pdb|5DE2|A 30 9e-31 122 
MAP2K1 pdb|3SLS|A 28 2e-30 121 
STK3 pdb|6AO5|A 29 3e-30 122 
MAPKAPK2 pdb|2JBO|A 32 3e-30 121 
PIM3 NP_001001852.2 30 6e-30 120 
MEK3 AAB41729.1 32 1e-29 124 
Nek6 AAG13417.1 27 2e-29 123 
CASK pdb|3MFR|A 28 3e-29 119 
Nek8 NP_835464.1 31 4e-29 122 
PNCK AAH64422.1 34 1e-28 115 
SPEG kinase NP_005867.3 32 2e-28 121 
PAK1 AAC50590.1 28 2e-28 119 
PAK4 AAH02921.1 27 2e-28 118 
PAK7 AAH24179.1 30 2e-28 120 





CAMKV AAH00497 26 3e-28 119 
STK11 NP_000446.1 28 4e-28 117 
MKNK2 pdb|2AC5|A 29 4e-28 115 
Nek9 NP_149107.4 29 7e-28 119 
PIM-2 pdb|2IWI|A 29 1e-27 114 
MAP3K5 pdb|2CLQ|A 29 9e-28 114 
PIM-1 pdb|4BZN|A 29 2e-27 113 
LATS1 NP_001337268.1 30 3e-27 117 
MAP3K8 NP_001231063.1 31 7e-27 114 
MAP3K6 AAI09033.1 27 1e-26 114 
CDK13 NP_003709.3 28 1e-26 115 
TAOK1 NP_079418.1 31 1e-26 115 
MAP3K2 NP_001358839.1 29 1e-26 115 
TAOK3 pdb|6BDN|A 32 3e-26 110 
MAP3K4 AAI43736.1 27 4e-26 114 
CDK16 AAH06190.1 26 5e-26 112 
TAOK2 NP_004774.1 32 1e-25 112 
MAP3K3 pdb|5J5T|A 27 2e-25 109 
LATS2 NP_055387.2 30 2e-25 111 
PASK NP_001239051.1 29 3e-25 111 
OSR1 NP_005100.1 28 2e-24 107 







Appendix 3: Initial virtual screening hits at the salt bridge binding site taken 
forward for investigation 
Compound ID Stock concentration 
(mM) 
Compound ID Stock 
concentration (mM) 
AC11871 100.00 AC16190 100.00 
AC42061 110.62 CC70663 100.00 
CC47846 109.93 CC68213 100.00 
CC26813 144.43 CC52213 100.00 
CC00713 127.53 CC00813 100.00 
CC01963 110.72 AC25987 100.00 
CC08909 125.42 CC02113 100.00 
CC60513 100.00 SEW03804 100.00 
CC61313 90.03 CC66813 100.00 
CC61963 111.22 CC06363 100.00 
CC66913 104.34 CC35563 100.00 
CC71601 46.74 CC30613 100.00 
MAY00096 173.83 CC13813 100.00 
BTB10042 86.68 CC00913 100.00 
CC42545 67.37 CC25513 100.00 
CC75719 87.64 MO01167 100.00 
MO08563 71.22 CC29313 100.00 
AC39789 66.24 KM05166 100.00 





AC12261 194.17 SP01447 100.00 
AC10026 62.83 CC21913 100.00 
AC29626 99.93 BTBG00035 100.00 
AC33758 76.23 MO07746 100.00 
AC34683 186.01 BTB13426 100.00 
AC37311 65.37 TL00150 100.00 
AC42043 73.12 BTB00733 100.00 
AC42399 49.64 AC39858 100.00 
CC49713 120.65 SEW05227 100.00 
CC14713 193.68 CC24413 100.00 
AW00189 67.52 BTB10558 100.00 
BTB13068 82.04 KM10724 100.00 
AC13217 115.21 AC10460 100.00 
AC15193 144.53 AC36409 100.00 
RH00879 123.93 RH00729 100.00 
BTB13009 64.63 CC65813 100.00 
BTB07041 137.07 MO01181 100.00 
HTS09269 77.79 S01381 100.00 
RH01534 124.64 CC56046 100.00 
RH01844 126.20 HTS00626 100.00 
RJC00373 89.00 CC13546 100.00 
SEW04444 121.99 CC58701 100.00 





RJC04046 83.67 AC33438 100.00 
SEW01483 135.56 BTB10358 100.00 
HTS01520 134.03 RH00001 100.00 
AC39841 172.63 CC40996 100.00 
BTB14320 51.98 TL00838 100.00 
DP01481 106.01 BTB06289 100.00 
RF03300 106.77 KM08985 100.00 
CC00413 130.26 CC12296 100.00 
GK01607 99.26 MO08374 100.00 
BTB02424 113.84 BTB04350 100.00 
CC07114 100.00 MO08607 100.00 
CC65063 100.00 10M-523S 100.00 
CC61114 100.00 AS-5557 100.00 
AC15782 100.00 FS-2138 100.00 
CD10231 100.00 PS-4320 100.00 
CD04945 104.71 PS-3600 100.00 
DSHS01050 83.82 PS-4439 100.00 
SB01866 165.5 FS-1321 100.00 
CC29716 118.99 PS-3424 100.00 
PS-3756 100.00 1R-1190 100.00 
PS-3417 100.00 AS-5528 100.00 







Appendix 4: Crystallography values (provided by Dr Syed Ahanger) 
Table 9.2 Crystal data for bound fragments 
Compound R work R free B factor 
BTB10042 20.2 23.1 60.0 
AC36409 20.1 24.6 69.0 
SEW03804 23.3 29.5 62.0 
 
